[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 839
1. Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M: Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol; 2010 Jan;220(1):58-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The malignant transformation of the benign neurofibroma to MPNST is incompletely understood at the molecular level.
  • We have determined the gene expression signature for benign and malignant PNSTs and found that the major trend in malignant transformation from neurofibroma to MPNST consists of the loss of expression of a large number of genes, rather than widespread increase in gene expression.
  • Relatively few genes are expressed at higher levels in MPNSTs and these include genes involved in cell proliferation and genes implicated in tumour metastasis.
  • Subsequent microRNA profiling of benign and malignant PNSTs indicated a relative down-regulation of miR-34a in most MPNSTs compared to neurofibromas.
  • [MeSH-major] Genes, p53. MicroRNAs / metabolism. Nerve Sheath Neoplasms / genetics. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adult. Apoptosis / genetics. Cell Adhesion / genetics. Cell Proliferation. Cluster Analysis. Down-Regulation. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neurofibroma. Oligonucleotide Array Sequence Analysis / methods. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction / genetics. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism


2. Maes L, Kalala JP, Cornelissen M, de Ridder L: Progression of astrocytomas and meningiomas: an evaluation in vitro. Cell Prolif; 2007 Feb;40(1):14-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By verifying the proliferation capacity, human telomerase reverse transcriptase (hTERT) expression and in vitro invasion, in a group of highly malignant glioblastomas, benign meningiomas and astrocytomas, at the initial stage of progression, we have analysed putative progression in vitro for proliferation and telomerase expression.
  • MATERIALS AND METHODS: The relative proliferation status (visualized with Ki-67 antibodies) and presence of hTERT protein was analysed in 27 intracranial tumours (6 astrocytomas, 8 glioblastomas and 13 meningiomas) by immunohistochemistry on paraffin-embedded biopsy tissue, as well as on primary tumour-derived cell cultures.
  • The group of benign meningiomas had a labelling index of 2.2 (SD = 2.7).
  • The group of benign meningiomas had a labelling index of 12.4 (SD = 19.2) for hTERT.
  • No difference was seen between the group of invasive and non-invasive tumour-derived cell cultures for the histopathological markers Ki-67 and hTERT (P > 0.05) in vitro.
  • CONCLUSIONS: The elevated expression of hTERT and Ki-67 in vitro provides a potential prognostic tool for early detection of the progression of brain tumours.
  • As tumour cells require telomerase for continued proliferation, the expression of hTERT may mark immortality, leading to indefinite life span.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cell Proliferation. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Telomerase / analysis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17227292.001).
  • [ISSN] 0960-7722
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


3. Vogelbaum MA, Leland Rogers C, Linskey MA, Mehta MP: Opportunities for clinical research in meningioma. J Neurooncol; 2010 Sep;99(3):417-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, when benign, are commonly treated with surgical resection alone.
  • However, the optimal treatment for patients with subtotally resected or recurrent World Health Organization (WHO) grade I tumors, or WHO grade II and III tumors, regardless of the extent of resection, is not well defined, with both a paucity of high quality published evidence as well as a perceived minimal clinical effect for currently available interventions, specifically in terms of prolonging survival.
  • In consideration of the size of the patient population with incompletely treated or non-benign meningiomas, there are opportunities for conducting high quality, prospective, multicenter clinical trials.
  • [MeSH-major] Biomedical Research. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Neuro Oncol. 2009 Dec;11(6):853-60 [19293394.001]
  • [Cites] Br J Neurosurg. 2007 Dec;21(6):588-92 [18071986.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):567-74; discussion 574-5 [10719852.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Neurooncol. 2010 Jan;96(2):211-7 [19562255.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Neurosurg Focus. 2003 May 15;14 (5):e4 [15669815.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 20835750.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Buchanich JM, Youk AO, Marsh GM, Kennedy KJ, Esmen NA, Lacey SE, Hancock R, Cunningham MA, Lieberman FS, Fleissner ML: Long-term health experience of jet engine manufacturing workers: IV. A comparison of central nervous system cancer ascertainment using mortality and incidence data. Ann Epidemiol; 2010 Oct;20(10):759-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To compare ascertainment of central nervous system (CNS) neoplasms with the use of mortality and incidence data as part of an occupational epidemiology study.
  • Compared with state cancer registries, death certificates missed 38% of the malignant, more than six times the benign and nearly 1.5 times the unspecified CNS cases.
  • The positive predictive value of death certificates, with cancer registry as gold standard, was 6% for unspecified, 35% for benign, and 86% for malignant histologies.
  • CONCLUSIONS: Death certificates seriously underascertained benign and unspecified CNS tumors; analyses determined with mortality data would not accurately capture the true extent of disease among the cohort.
  • Most state cancer registries have only collected nonmalignant CNS tumor information since 2004, which currently limits the usefulness of state cancer registries as a source of nonmalignant CNS tumor identification.
  • [MeSH-major] Brain Neoplasms / epidemiology. Cranial Nerve Neoplasms / epidemiology. Death Certificates. Occupational Exposure. Registries / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Occupational Health.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20816315.001).
  • [ISSN] 1873-2585
  • [Journal-full-title] Annals of epidemiology
  • [ISO-abbreviation] Ann Epidemiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Tsurubuchi T, Yamamoto T, Tsukada Y, Matsuda M, Nakai K, Matsumura A: Meningioma associated with Werner syndrome--case report--. Neurol Med Chir (Tokyo); 2008 Oct;48(10):470-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Screening brain magnetic resonance (MR) imaging with gadolinium had detected multiple homogeneously enhanced tumors in the right convexity and in the anterior and posterior thirds of the falx cerebri after surgery for osteosarcoma in his right leg at age 52 years.
  • Ten months later, the right convexity tumor was removed because follow-up MR imaging detected tumor growth.
  • The histological diagnosis was transitional meningioma.
  • Most meningiomas associated with Werner syndrome are benign, but are sometimes complicated with extracranial tumors such as sarcoma, thyroid carcinoma, and others.
  • Patients with meningioma associated with Werner syndrome should be carefully followed up to detect the occurrence of other extracranial tumors such as sarcoma by brain MR imaging, echography, or body computed tomography.
  • [MeSH-major] Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology. Werner Syndrome / complications


6. Wang Y, Yamada K, Tanaka Y, Ishikawa K, Inagaki N: Expression of ABCA2 protein in human vestibular schwannoma and peripheral nerve. J Neurol Sci; 2005 May 15;232(1-2):59-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ABCA2, which belongs to the A subclass of the ATP-binding cassette (ABC) transporter superfamily, is predominantly expressed in the cytoplasm of oligodendrocytes and Schwann cells, the myelin-forming cells in brain and peripheral nerve, respectively.
  • Here, we demonstrate by immunoblot and immunohistochemistry that ABCA2 is expressed in benign vestibular schwannomas, which contain neither axons nor compact myelin.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Ear Neoplasms / metabolism. Neuroma, Acoustic / metabolism. Peripheral Nerves / metabolism

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15850583.001).
  • [ISSN] 0022-510X
  • [Journal-full-title] Journal of the neurological sciences
  • [ISO-abbreviation] J. Neurol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / ABCA2 protein, human; 0 / ATP-Binding Cassette Transporters; 0 / Biomarkers; 0 / Myelin Basic Protein; 0 / Neurofilament Proteins; 0 / Receptor, Nerve Growth Factor; 0 / S100 Proteins
  •  go-up   go-down


7. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.
  • Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible.
  • For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


8. Sheridan T, Herawi M, Epstein JI, Illei PB: The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate. Am J Surg Pathol; 2007 Sep;31(9):1351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
  • It is expressed in both benign and neoplastic prostate tissues, but not in any other normal or malignant tissue examined to date.
  • The tissue microarray contains 78 cases of metastatic prostatic adenocarcinoma, 20 cases of primary prostatic adenocarcinoma, and 20 cases of benign prostate tissue from the peripheral zone as well as samples of benign brain, pancreas, kidney, thyroid, testis, skeletal muscle, and fibroconnective tissue.
  • RESULTS: Similar staining (intensity and extent) was identified for both markers in the majority of metastatic tumors (11 distant sites, 42 pelvic lymph nodes), in all 20 primary tumors and in all benign prostate and nonprostate tissues.
  • The P501S stain had perinuclear cytoplasmic (Golgi) distribution even in poorly differentiated tumors and metastases.
  • None of the tumors were negative for both markers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Membrane Proteins / analysis. Neoplasms, Unknown Primary / diagnosis. Prostate-Specific Antigen / analysis. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Cell Differentiation. Golgi Apparatus / chemistry. Humans. Immunohistochemistry. Lymph Nodes / chemistry. Lymph Nodes / immunology. Male. Neoplasm Staging. Predictive Value of Tests. Reproducibility of Results. Sensitivity and Specificity. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17721190.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA58236
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / prostein; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


9. Charles-Edwards EM, deSouza NM: Diffusion-weighted magnetic resonance imaging and its application to cancer. Cancer Imaging; 2006;6:135-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In cancer imaging DW-MRI has been used to distinguish brain tumours from peritumoural oedema.
  • It is also increasingly exploited to differentiate benign and malignant lesions in liver, breast and prostate where increased cellularity of malignant lesions restricts water motion in a reduced extracellular space.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Neoplasms / pathology
  • [MeSH-minor] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Female. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / pathology. Humans. Image Processing, Computer-Assisted. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Male. Prostatic Neoplasms / diagnosis. Prostatic Neoplasms / pathology. Treatment Outcome. Whole Body Imaging

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) International Cancer Imaging Society.
  • [Cites] Neoplasia. 1999 Jun;1(2):113-7 [10933044.001]
  • [Cites] Eur Radiol. 2006 Sep;16(9):1898-905 [16691378.001]
  • [Cites] J Neurooncol. 2000 Dec;50(3):215-26 [11263501.001]
  • [Cites] J Magn Reson Imaging. 2001 Apr;13(4):534-46 [11276097.001]
  • [Cites] Radiology. 2001 Jun;219(3):842-9 [11376280.001]
  • [Cites] Radiology. 2001 Sep;220(3):621-30 [11526259.001]
  • [Cites] Magn Reson Med. 2001 Dec;46(6):1054-8 [11746568.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):307-8 [12147376.001]
  • [Cites] J Magn Reson Imaging. 2002 Aug;16(2):172-8 [12203765.001]
  • [Cites] Radiology. 2003 Jan;226(1):71-8 [12511671.001]
  • [Cites] Eur J Radiol. 2003 Mar;45(3):208-13 [12595105.001]
  • [Cites] Mol Imaging. 2002 Oct;1(4):336-43 [12926229.001]
  • [Cites] Neoplasia. 2004 Mar-Apr;6(2):136-42 [15140402.001]
  • [Cites] NMR Biomed. 2004 Jun;17(4):170-80 [15229930.001]
  • [Cites] J Magn Reson Imaging. 2004 Oct;20(4):654-61 [15390142.001]
  • [Cites] Radiat Med. 2004 Jul-Aug;22(4):275-82 [15468951.001]
  • [Cites] Radiology. 1986 Nov;161(2):401-7 [3763909.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 May;11(3):423-9 [2161612.001]
  • [Cites] Magn Reson Med. 1997 Apr;37(4):576-81 [9094080.001]
  • [Cites] Radiology. 1997 Sep;204(3):739-44 [9280252.001]
  • [Cites] NMR Biomed. 1999 Feb;12(1):51-62 [10195330.001]
  • [Cites] Neuroimaging Clin N Am. 1999 May;9(2):343-61 [10318719.001]
  • [Cites] Anat Rec. 1999 Jun 15;257(3):102-9 [10397783.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):831-7 [15720810.001]
  • [Cites] Radiology. 2005 Mar;234(3):756-64 [15734932.001]
  • [Cites] Magn Reson Med Sci. 2004 Jul 15;3(2):79-85 [16093623.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):644-9 [16163035.001]
  • [Cites] Nihon Hoshasen Gijutsu Gakkai Zasshi. 2005 Nov 20;61(11):1551-8 [16317416.001]
  • [Cites] Br J Cancer. 2006 Feb 13;94(3):427-35 [16465174.001]
  • [Cites] Radiology. 2006 Jun;239(3):632-49 [16714455.001]
  • [Cites] J Natl Cancer Inst. 2000 Dec 20;92(24):2029-36 [11121466.001]
  • (PMID = 17015238.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1693785
  •  go-up   go-down


10. Yoshikawa G, Kawamoto S, Yakou K, Tsutsumi K: Massive intracranial hemorrhage associated with pleomorphic xanthoastrocytoma--case report. Neurol Med Chir (Tokyo); 2010;50(3):220-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had been treated with anticonvulsant medication under a diagnosis of left mesial temporal sclerosis based on magnetic resonance imaging findings.
  • Cerebral angiography on admission revealed occlusion of the P(2) segment of the left posterior cerebral artery (PCA) and extravasation of contrast medium during the procedure.
  • Presumably the bleeding was caused by the rupture of a pseudoaneurysm secondary to leptomeningeal involvement of this typically benign tumor.
  • [MeSH-major] Aneurysm, False / etiology. Aneurysm, Ruptured / etiology. Astrocytoma / complications. Brain Neoplasms / complications. Hematoma, Subdural, Intracranial / etiology. Subarachnoid Hemorrhage / etiology
  • [MeSH-minor] Cerebral Angiography. Female. Humans. Middle Aged. Posterior Cerebral Artery. Severity of Illness Index. Temporal Lobe / blood supply. Temporal Lobe / pathology. Temporal Lobe / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Pleomorphic xanthoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339272.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Motta FJ, Valera ET, Lucio-Eterovic AK, Queiroz RG, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Marie SK, Tone LG: Differential expression of E-cadherin gene in human neuroepithelial tumors. Genet Mol Res; 2008;7(2):295-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of E-cadherin gene in human neuroepithelial tumors.
  • This study aimed to evaluate the expression of E-cadherin and their correlation with clinical features in microdissected brain tumor samples from 81 patients, divided into 62 astrocytic tumors grades I to IV and 19 medulloblastomas, and from 5 white matter non-neoplasic brain tissue samples.
  • We observed a decrease in expression among pathological grades of neuroepithelial tumors.
  • Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than did neuroepithelial tumors.
  • Expression of E-cadherin gene was higher in astrocytic than embryonal tumors (P = 0.0168).
  • Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than grade I malignancy astrocytomas, considered as benign tumors (P = 0.0473).
  • These results suggest that a decrease in E-cadherin gene expression level in high-grade neuroepithelial tumors may be a hallmark of malignancy in dedifferentiated tumors and that it may be possibly correlated with their progression and dissemination.
  • [MeSH-major] Cadherins / genetics. Gene Expression Profiling. Neoplasms, Neuroepithelial / genetics
  • [MeSH-minor] Adolescent. Adult. Brain / metabolism. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551395.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  •  go-up   go-down


12. Komoribayashi N, Arai H, Kojo T, Obonai C, Wakabayashi J, Ogawa A: [Subfrontal schwannoma: case report]. No Shinkei Geka; 2005 Jun;33(6):601-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannoma are benign, slowly growing nerve sheath tumors.
  • The left carotid angiography revealed that the tumor was supplied from the anterior ethomoidal artery, but no remarkable tumor stain was detected.
  • Bifrontal craniotomy with total excision of the tumor revealed a tumor in the left subfrontal lesion.
  • The tumor was attached to the falx, the left frontal lobe, and the skull base, but those structures were not invaded.
  • Subsequent histological examination proved that this tumor was schwannoma.
  • Further cases of subfrontal schwannoma are necessary to solve the enigma of the origin of this tumor.
  • [MeSH-major] Brain Neoplasms / surgery. Neurilemmoma / surgery
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Frontal Lobe / pathology. Humans. Magnetic Resonance Imaging. Neurosurgical Procedures / methods

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952309.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 28
  •  go-up   go-down


13. Rieske P, Zakrzewska M, Biernat W, Bartkowiak J, Zimmermann A, Liberski PP: Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome. J Neurooncol; 2005 Jan;71(1):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed three neoplasms with completely different histologies: malignant fibrous histiocytoma (MFH), atypical meningioma (AM), and glioblastoma (GB), developing in a patient with Li-Fraumeni syndrome.
  • [MeSH-major] Germ-Line Mutation. Glioblastoma / genetics. Histiocytoma, Benign Fibrous / genetics. Li-Fraumeni Syndrome / genetics. Meningioma / genetics. Neoplasms, Multiple Primary / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Brain Neoplasms / genetics. Brain Neoplasms / therapy. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 22 / genetics. DNA / analysis. Fatal Outcome. Genetic Testing. Humans. Loss of Heterozygosity. Male. Microsatellite Repeats. Skin Neoplasms / genetics. Skin Neoplasms / therapy


14. Asano K, Takeda T, Nakano T, Ohkuma H: Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors. Brain Tumor Pathol; 2010 Apr;27(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors.
  • MIB-1 staining provides a useful index of the malignancy of brain tumors.
  • However, because of the difficulty of evaluating malignancy based on the preoperative imaging findings, we investigated the correlation between the (201)Tl-SPECT retention index (RI) and MIB-1 staining index (MIB-1 SI) to determine the usefulness of RI for preoperative evaluation of the malignancy of brain tumors.
  • The subjects of this study were 47 patients who underwent tumor removal surgery at our hospital in 2006 and 2007.
  • The tumors consisted of 16 intraaxial tumors (all gliomas: 9 glioblastomas, 2 anaplastic astrocytomas, 2 anaplastic oligoastrocytomas, 1 oligodendroglioma, and 2 ependymomas), 8 other malignant brain tumors, and 23 extraaxial tumors (10 meningiomas, 7 pituitary adenomas, and 6 schwannomas).
  • The mean RI and mean MIB-1 SI of the intraaxial tumors were 0.628% and 32.0%, respectively, and after MIB-1 SI was converted to the natural logarithm (log MIB-1 SI), Pearson's coefficient for the correlation between them was significant (r = 0.752, P < 0.001).
  • The mean RI and mean MIB-1 SI of the extraaxial tumors were 0.377% and 3.01%, respectively, and after MIB-1 SI was converted to log MIB-1 SI, Pearson's coefficient for the correlation between them was significant (r = 0.803, P < 0.001).
  • Thus, the MIB-1 SI values of highly malignant intraaxial tumors was strongly correlated with their RI values, and the (201)Tl-SPECT RI values were useful as an index of malignancy.
  • RI values may also be useful for evaluating apparently benign extraaxial tumors for possible malignancy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Ki-67 Antigen / analysis. Preoperative Period. Staining and Labeling. Tomography, Emission-Computed, Single-Photon

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425041.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes
  •  go-up   go-down


15. Schoch B, Hogan A, Gizewski ER, Timmann D, Konczak J: Balance control in sitting and standing in children and young adults with benign cerebellar tumors. Cerebellum; 2010 Sep;9(3):324-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balance control in sitting and standing in children and young adults with benign cerebellar tumors.
  • Balance control was assessed in 16 patients after surgery of a benign cerebellar tumor in chronic state and healthy age- and gender-matched control subjects.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Neurosurgical Procedures / adverse effects. Postoperative Complications / physiopathology. Postural Balance

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1955 Dec;74(6):653-80 [13268132.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):813-9 [15378041.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Sep;73(3):310-2 [12185166.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):601-10 [9778258.001]
  • [Cites] Prog Brain Res. 2004;143:353-66 [14653179.001]
  • [Cites] Neuropediatrics. 2006 Dec;37(6):350-8 [17357037.001]
  • [Cites] Neuroscientist. 2004 Jun;10(3):247-59 [15155063.001]
  • [Cites] J Neurophysiol. 2003 Apr;89(4):1844-56 [12612041.001]
  • [Cites] Cereb Cortex. 2004 Oct;14(10):1164-72 [15142954.001]
  • [Cites] Cerebellum. 2008;7(4):602-6 [18949530.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):421-5 [10199329.001]
  • [Cites] Neuroimage. 2006 Mar;30(1):36-51 [16253526.001]
  • [Cites] Annu Rev Neurosci. 1992;15:403-42 [1575449.001]
  • [Cites] Brain. 2005 Jun;128(Pt 6):1428-41 [15659424.001]
  • [Cites] J Neurol Sci. 1997 Feb 12;145(2):205-11 [9094050.001]
  • [Cites] J Comp Neurol. 1955 Aug;103(1):105-29 [13263445.001]
  • [Cites] Neuroimage. 2002 Sep;17(1):240-55 [12482081.001]
  • [Cites] Neuroimage. 2001 Aug;14(2):486-500 [11467921.001]
  • [Cites] Mov Disord. 1998 Nov;13(6):958-64 [9827622.001]
  • [Cites] Brain. 2008 Nov;131(Pt 11):2913-27 [18835866.001]
  • [Cites] Mov Disord. 2005 Aug;20(8):1006-13 [15838852.001]
  • [Cites] Magn Reson Med. 1998 Jul;40(1):143-51 [9660564.001]
  • (PMID = 20352395.001).
  • [ISSN] 1473-4230
  • [Journal-full-title] Cerebellum (London, England)
  • [ISO-abbreviation] Cerebellum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Spurlock G, Griffiths S, Uff J, Upadhyaya M: Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types. Fam Cancer; 2007;6(4):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Somatic alterations of the NF1 gene in an NF1 individual with multiple benign tumours (internal and external) and malignant tumour types.
  • We have carried out NF1 gene mutation analysis on DNA isolated from 25 tumours (dermal and plexiform neurofibromas, malignant peripheral nerve sheath tumour, MPNST), obtained at post-mortem from an NF1 patient.
  • Of the 25 tumours studied from this patient, characterised somatic mutations were identified in 9 tumours, these were six small deletions (748del T, 2534-2557 del 24bp, 2843delA, 3047-3048 del GT, 4743del G, 7720-7721 delAA), an insertion 649 ins 73 bp, a non-sense mutation R1513X and a single splice site mutation, IVS4C-1 G>A, eight of these represent novel sequence changes in the gene.
  • Each of the tumours analysed contained a different somatic NF1 mutation, indicating that each tumour is the result of an independent somatic event.
  • [MeSH-major] Mutation / genetics. Neoplasms / genetics. Neoplasms / pathology. Neurofibromin 1 / genetics
  • [MeSH-minor] Adolescent. Adult. Alleles. Base Sequence. Child, Preschool. Chromatography, High Pressure Liquid. Exons / genetics. Gene Deletion. Humans. Microsatellite Instability. Molecular Sequence Data. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain. 1988 Dec;111 ( Pt 6):1355-81 [3145091.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Oct;45(10):893-904 [16830335.001]
  • [Cites] Hum Genet. 2003 Feb;112(2):117-23 [12522551.001]
  • [Cites] Hum Mutat. 2003 Dec;22(6):423-7 [14635100.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Hum Mol Genet. 2000 Jan 22;9(2):237-47 [10607834.001]
  • [Cites] Am J Hum Genet. 2000 Feb;66(2):393-401 [10677298.001]
  • [Cites] Hum Genet. 2001 May;108(5):416-29 [11409870.001]
  • [Cites] Am J Med Genet. 1997 May 16;70(2):138-43 [9128932.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):111-6 [14722914.001]
  • [Cites] Acta Derm Venereol. 1995 Mar;75(2):136-40 [7604643.001]
  • [Cites] Nature. 1989 Dec 7;342(6250):705-8 [2531845.001]
  • [Cites] Nat Genet. 2001 Jul;28(3):294-6 [11431704.001]
  • [Cites] Hum Mutat. 2004 Feb;23(2):134-46 [14722917.001]
  • [Cites] Hum Mutat. 2006 Oct;27(10 ):1030-40 [16941471.001]
  • [Cites] Hum Mutat. 1997;9(5):458-64 [9143927.001]
  • [Cites] Am J Hum Genet. 1997 Sep;61(3):512-9 [9326316.001]
  • [Cites] Nucleic Acids Res. 1991 Dec 25;19(24):6977 [1762941.001]
  • [Cites] Nucleic Acids Res. 2002 Jun 15;30(12 ):e57 [12060695.001]
  • [Cites] Biochem Biophys Res Commun. 1997 May 19;234(2):346-50 [9177273.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):290-3 [9927033.001]
  • [Cites] Cancer Res. 2002 Mar 1;62(5):1573-7 [11894862.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):359-62 [11809679.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Aug;28(4):425-31 [10862051.001]
  • [Cites] N Engl J Med. 1986 Apr 17;314(16):1010-5 [3083258.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):122-6 [8499945.001]
  • [Cites] Cell. 2001 Feb 23;104(4):593-604 [11239415.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Mar;45(3):265-76 [16283621.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Aug;113(1):65-9 [10459349.001]
  • [Cites] Science. 2002 May 3;296(5569):920-2 [11988578.001]
  • [Cites] Cancer Res. 1999 Jan 15;59(2):294-7 [9927034.001]
  • [Cites] Hum Mol Genet. 2000 Dec 12;9(20):3055-64 [11115850.001]
  • [Cites] J Med Genet. 2000 Jan;37(1):44-9 [10633134.001]
  • [Cites] Am J Hum Genet. 2000 Mar;66(3):790-818 [10712197.001]
  • [Cites] Hum Mutat. 2000;15(6):541-55 [10862084.001]
  • [Cites] Am J Hum Genet. 1994 Mar;54(3):424-36 [8116612.001]
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Nat Genet. 1996 Sep;14(1):110-2 [8782831.001]
  • [Cites] Hum Mol Genet. 2001 Jun 15;10(13):1387-92 [11440991.001]
  • [Cites] Nat Genet. 1995 Sep;11(1):90-2 [7550323.001]
  • (PMID = 17551851.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neurofibromin 1; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


17. Anker CJ, Shrieve DC: Basic principles of radiobiology applied to radiosurgery and radiotherapy of benign skull base tumors. Otolaryngol Clin North Am; 2009 Aug;42(4):601-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic principles of radiobiology applied to radiosurgery and radiotherapy of benign skull base tumors.
  • Various types of ionizing radiation may be used therapeutically for benign skull base tumors.
  • These basic radiobiological tenets are discussed in this chapter, with the focus on radiotherapy of benign skull base tumors.
  • Animal and clinical data, however, acquired from the radiation of malignant tumors are necessarily included, as they comprise much of our knowledge of fractionation schedules, central nervous system (CNS) toxicity, and CNS volume effects.
  • [MeSH-major] Brain / pathology. Radiobiology / standards. Radiotherapy Planning, Computer-Assisted / standards. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19751867.001).
  • [ISSN] 1557-8259
  • [Journal-full-title] Otolaryngologic clinics of North America
  • [ISO-abbreviation] Otolaryngol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 88
  •  go-up   go-down


18. Chen H, Sun XF, Wu JS: [Clinicopathologic study of subependymal giant cell astrocytoma]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):656-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor often occurred in the lateral ventricles (16/18, 88.9%).
  • CONCLUSIONS: Subependymal giant cell astrocytoma is a benign brain tumor with distinctive histopathologic features.
  • The tumor typically affects children and young adults.
  • [MeSH-major] Astrocytoma / pathology. Cerebral Ventricle Neoplasms / pathology

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374208.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Synaptophysin
  •  go-up   go-down


19. Coope DJ, Cízek J, Eggers C, Vollmar S, Heiss WD, Herholz K: Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map. J Nucl Med; 2007 Dec;48(12):1971-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of primary brain tumors using 11C-methionine PET with reference to a normal methionine uptake map.
  • (11)C-Methionine PET is a well-established technique for evaluating tumor extent for diagnosis and treatment planning in neurooncology.
  • Image interpretation is typically performed using the ratio of uptake within the tumor to a reference region.
  • Selection of a reference region can be highly user dependant, and identifying a representative normal region may be complicated by midline or multifocal tumors.
  • We hypothesized that current coregistration methods would enable interpretation of methionine PET images with reference to an averaged normal uptake map, allowing better standardization of scan analysis and increasing the sensitivity to tumor infiltration, particularly of white matter regions.
  • METHODS: A normal methionine uptake map was prepared from the normal hemispheres of 20 scans performed on patients with benign or low-grade lesions.
  • A standardized method for applying the normal uptake map in brain tumors was developed and evaluated in a sample of 18 scans (6 grade II, 6 grade III, and 6 grade IV gliomas).
  • Tumor extent was compared with that derived from a mirrored contralateral reference region method.
  • Correlation coefficients were calculated between the uptake ratios for tumor to normal uptake map versus tumor to mirrored reference region.
  • Uptake ratios within the tumor varied slightly with the normalization methods used but correlated closely with the ratio to a single reference value.
  • The tumor uptake ratios obtained correlated closely with a standard reference value technique, whereas the described method allowed for better standardization of the image analysis.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Image Processing, Computer-Assisted / standards. Methionine / pharmacokinetics. Positron-Emission Tomography / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006617.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; AE28F7PNPL / Methionine
  •  go-up   go-down


20. Jinhu Y, Jianping D, Jun M, Hui S, Yepeng F: Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature. J Neurooncol; 2007 May;83(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature.
  • Cerebrospinal metastases of benign choroid plexus papillomas (CPPs) are extremely rare.
  • Plain CT scan of the cranium revealed a partly calcified tumor filling the fourth ventricle and its right recess.
  • Cranial MRI showed an inhomogeneously contrast-enhancing tumor and leptomeningeal enhancement encasing the brain stem.
  • Complete resection of the tumor was carried out, and seedings to the floor of the fourth ventricle and cervico-medullary junction were found during the operation.
  • While intraoperative frozen section suggested pathology of papillary ependymoma or CPP, to our surprise, final histological examination revealed a benign choroid plexus papilloma.
  • Two months after the first operation, on follow-up MRI of the cranium, the leptomeningeal enhancement encasing the brain stem had resolved spontaneously.
  • This special case helps increase our understanding of benign CPPs and expands our differential diagnostic consideration of lesions with similar manifestations.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Cerebral Ventricle Neoplasms / secondary. Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / secondary. Fourth Ventricle. Papilloma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Seeding. Neurosurgical Procedures / adverse effects. Subarachnoid Space. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1970 Nov;110(3):608-17 [5489698.001]
  • [Cites] Surg Neurol. 1999 Jun;51(6):621-9 [10369230.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):956-63 [11035346.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Sep;100(3):165-86 [9822838.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jan;33(1):32-5 [7680781.001]
  • [Cites] Neurochirurgie. 1986;32(3):258-61 [3762840.001]
  • [Cites] Neurosurg Focus. 2006 Jan 15;20(1):E10 [16459990.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jul;101(7):366-8 [577391.001]
  • [Cites] Neuroradiology. 2000 Sep;42(9):657-61 [11071438.001]
  • [Cites] Pediatr Neurosci. 1985-1986;12(4-5):196-201 [3843618.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]
  • [Cites] Br J Radiol. 1992 Sep;65(777):754-7 [1393408.001]
  • [Cites] Neurology. 2005 Sep 27;65(6):842 [16186520.001]
  • [Cites] J Neurosurg. 1960 Nov;17:1002-27 [13768200.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):85-90 [8744814.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):564-5 [2058519.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 May-Jun;8(3):469-72 [3111207.001]
  • [Cites] Surg Neurol. 1982 Nov;18(5):367-71 [6983728.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):723-8 [12181706.001]
  • [Cites] Neurology. 1995 Oct;45(10):1801-7 [7477972.001]
  • [Cites] Neurosurg Rev. 1981;4(3):129-37 [7301142.001]
  • [Cites] Aust N Z J Med. 1997 Oct;27(5):597-8 [9404596.001]
  • [Cites] Folia Neuropathol. 2001;39(3):209-13 [11770132.001]
  • [Cites] Surg Neurol. 1987 May;27(5):466-8 [3563861.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):633-8 [8010262.001]
  • (PMID = 17387433.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


21. McGovern SL, Aldape KD, Munsell MF, Mahajan A, DeMonte F, Woo SY: A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. J Neurosurg; 2010 May;112(5):925-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas.
  • The goal of this study was to identify clinical characteristics associated with the recurrence of benign meningiomas and their acceleration to atypical and malignant histological types.
  • Consequently, patients with Grade I non-skull base cranial meningiomas had better 5-year recurrence-free survival (69%) than patients with Grade I skull base meningiomas (56%) or Grade II or III tumors at any site (50%; p = 0.005).
  • Unexpectedly, patients with non-skull base tumors who experienced a recurrence (8 of 22 [36%]) were more likely than patients with skull base tumors (1 of 19 [5%]) to have a higher grade tumor at recurrence (p = 0.024).
  • Furthermore, the median MIB-1 labeling index of Grade I non-skull base cranial meningiomas (2.60%) was significantly higher than that of Grade I skull base tumors (1.35%; p = 0.016).
  • CONCLUSIONS: Cranial meningiomas that occur outside of the skull base are more likely to have a higher MIB-1 labeling index and recur with a higher grade than those within the skull base, suggesting that non-skull base cranial tumors may have a more aggressive biology than skull base tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local. Skull Base Neoplasms / pathology. World Health Organization
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Staging. Neurosurgical Procedures. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19799498.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Alam E, Wilson RD, Vargo MM: Inpatient cancer rehabilitation: a retrospective comparison of transfer back to acute care between patients with neoplasm and other rehabilitation patients. Arch Phys Med Rehabil; 2008 Jul;89(7):1284-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inpatient cancer rehabilitation: a retrospective comparison of transfer back to acute care between patients with neoplasm and other rehabilitation patients.
  • OBJECTIVE: To determine whether patients with diagnoses of neoplasm undergoing acute rehabilitation differ from other patients in frequency of acute care transfer and type of medical complications.
  • PARTICIPANTS: Patients with diagnosis of neoplasm (n=40) and patients without neoplasm (n=253) requiring transfer were identified from a database of 2801 rehabilitation discharges over nearly a 4-year period.
  • RESULTS: Significant difference occurred in overall rate of transfer between patients with neoplasm (21%) and controls (9.7%; P<.001).
  • When evaluated separately for type of neoplasm (with patients receiving corresponding type of rehabilitation as controls), a significantly higher rate of transfer to acute care was found for brain tumor (25% vs 12%; P=.004) and spinal cord neoplasms (23% vs 10%; P=.009), but statistical significance was not reached for other tumor types (12.5% vs 7.4%; P=.19).
  • Patients with stroke with neoplasm as a comorbidity, analyzed separately, with the other patients with stroke as controls, had significantly higher risk of transfer (22% vs 10%; P=.012).
  • Logistic regression analysis found an odds ratio (OR) of 2.5 for unplanned transfer among patients with diagnosis of neoplasm (OR=2.5 for malignancy; OR=2.4 for benign neoplasm).
  • Patients with neoplasm had infection as the most common reason for transfer (28% of the neoplasm transfers vs 18% of other transfers; P=.01), whereas in the nonneoplasm group, cardiopulmonary factors predominated (12% of patients with tumor vs 31% of patients without tumor transfers; P<.001).
  • CONCLUSIONS: In the present sample, patients with neoplasm were more likely to require transfer than patients without neoplasm, although this pattern did not reach statistical significance for noncentral nervous system cases.
  • Overall, patients with neoplasm appear more likely than those without neoplasm to have an infectious cause for unplanned transfer.
  • [MeSH-major] Critical Care. Neoplasms / epidemiology. Neoplasms / rehabilitation. Patient Transfer
  • [MeSH-minor] Aged. Brain Neoplasms / epidemiology. Brain Neoplasms / rehabilitation. Cohort Studies. Comorbidity. Diabetes Mellitus / epidemiology. Female. Heart Diseases / epidemiology. Hospitalization. Humans. Logistic Models. Male. Middle Aged. Pulmonary Disease, Chronic Obstructive / epidemiology. Retrospective Studies. Spinal Cord Neoplasms / epidemiology. Stroke / epidemiology

  • MedlinePlus Health Information. consumer health - Critical Care.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586130.001).
  • [ISSN] 1532-821X
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12- HD01097
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


23. Tena-Suck ML, Moreno-Reyes I, Rembao D, Vega R, Moreno-Jiménez S, Castillejos-López Mde J, Fernández-Plata R, Martínez-Briseño D, Salinas-Lara C: [Clinical pathological study of craniopharyngioma. Fifteen years at the National Institute of Neurology and Neurosurgery "Manuel Velasco Suárez"]. Gac Med Mex; 2009 Sep-Oct;145(5):361-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Craneofaringioma, estudio clínico-patológico. Quince años del Instituto Nacional de Neurología y Neurocirugía "Manuel Velasco Suárez".
  • BACKGROUND: Craniopharyngioma is a sellar region benign cyst It's frequency ranges from 1.2% to 4.6% of all brain tumors.
  • OBJECTIVE: To carry out a clinical pathological correlation of craniopharyngioma among adults and describe the tumor's biological characteristics.
  • The mean patient age for recurrent tumors was 50.46+/-14.13yrs and 48.65+/-11.95 for non recurrent tumors.
  • Follow-up was longer among females than males and in suprasellar tumor location, papillary type, external epithelium cysts and laxo stellate reticulum.
  • CONCLUSIONS: However a good prognostic factor in craniopharyngiomas was observed in older female patients with complete exeresis, small tumors, external epithelium cysts, edematous stroma, inflammation, and absence of atypical cell and mitosis.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20073441.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


24. Al-Otaibi M, Lach B, Al Shail E: December 2004: one-year-old girl with aggressive skull tumor. Brain Pathol; 2005 Apr;15(2):171-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] December 2004: one-year-old girl with aggressive skull tumor.
  • December 2004. Twelve-month old girl presented with recurrent subcutaneous lesion in the left parietal region, one year after excision of a "benign" tumor.
  • An MRI demonstrated left temporo-parietal skull tumor infiltrating the soft tissue, surrounding craniotomy flap, and extending to the brain parenchyma.
  • Biopsy revealed biphasic neoplasm displaying nests of poorly differentiated neuroblastic cells positive for synaptophysin and pigmented cuboidal epithelioid cell positive for keratins, epithelial membrane antigen and MHB-45.
  • Interestingly, cell with the neuroblastic immunophenotype displayed 80% nuclear MIB-1 reactivity indicating that the aggressiveness of the neoplasm was confined mostly to this pattern of differentiation.
  • The overall histological features are consistent with a rare malignant variant of a melanotic neuroectodermal tumor of infancy.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Neuroectodermal Tumor, Melanotic / pathology. Parietal Bone / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Brain Neoplasms / secondary. Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Infant. Magnetic Resonance Imaging. Soft Tissue Neoplasms / secondary. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15912891.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Kernick D, Stapley S, Campbell J, Hamilton W: What happens to new-onset headache in children that present to primary care? A case-cohort study using electronic primary care records. Cephalalgia; 2009 Dec;29(12):1311-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At presentation, 9321 (19.2%) of headaches were labelled primary, 549 (1.1%) secondary and 38 705 (79.7%) received no formal diagnosis.
  • Of the latter group, 2084 (5.4%) received a primary headache diagnosis in the subsequent year.
  • Following a diagnosis of migraine, 258 (3.5%) had received a triptan and 1598 (21%) were using propranolol or pizotifen.
  • Headache was a risk factor for benign and malignant tumours, cerebrovascular disease, primary disorders of raised intracranial pressure and depression.
  • This risk was reduced if a diagnosis of a primary headache disorder could be made.
  • Although there is an increased likelihood of a serious pathology with headache presentations, the risk is small particularly if a diagnosis of a primary headache is made.
  • [MeSH-minor] Adolescent. Brain Neoplasms / epidemiology. Cerebrovascular Disorders / epidemiology. Child. Child, Preschool. Cohort Studies. Databases, Factual. Female. Humans. Hydrocephalus / epidemiology. Male. Prognosis

  • MedlinePlus Health Information. consumer health - Children's Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19911465.001).
  • [ISSN] 1468-2982
  • [Journal-full-title] Cephalalgia : an international journal of headache
  • [ISO-abbreviation] Cephalalgia
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


26. Salemi M, Calogero AE, Vicari E, Migliore E, Zaccarello G, Cosentino A, Amore M, Tricoli D, Castiglione R, Bosco P, Rappazzo G: A high percentage of skin melanoma cells expresses SPANX proteins. Am J Dermatopathol; 2009 Apr;31(2):182-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of SPANX (sperm protein associated with the nucleus in the X chromosome) gene family has been reported in many tumors, such as melanoma, myeloma, glioblastoma, breast carcinoma, ovarian cancer, testicular germ cell tumors, and hematological malignancies.
  • The expression of SPANX proteins was evaluated by immunohistochemistry in normal skin (n = 12), melanomas (n = 21), and benign nevi (n = 10), using a polyclonal antibody raised in our laboratory.
  • Benign nevi had an intermediate number of cells expressing SPANX proteins (25% +/- 8.5%), which resulted significantly higher than normal skin cells and significantly lower than skin melanoma cells.
  • In melanoma cells, the labeling was mostly nuclear, sometimes incomplete or limited to the perinuclear wall, even if cytoplasmic staining was also seen in SPANX-positive tumor cells.
  • [MeSH-major] Melanoma / metabolism. Nuclear Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies. Antibody Specificity. Biopsy. Epitopes / immunology. Epitopes / metabolism. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Multigene Family / physiology. Neoplasms / metabolism. Neoplasms / pathology. Nevus / metabolism. Nevus / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318807.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Epitopes; 0 / Nuclear Proteins; 0 / SPANXA1 protein, human
  •  go-up   go-down


27. Yao Z, Wang Y, Zee C, Feng X, Sun H: Computed tomography and magnetic resonance appearance of sporadic meningioangiomatosis correlated with pathological findings. J Comput Assist Tomogr; 2009 Sep-Oct;33(5):799-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Meningioangiomatosis (MA) is a rare benign localized lesion of leptomeninges and underlying cerebral cortex.
  • Preoperative diagnosis is difficult and challenging because of its diverse clinical, pathological, and imaging features.
  • [MeSH-major] Angiomatosis / diagnosis. Meningeal Neoplasms / blood supply. Meningeal Neoplasms / diagnosis. Meningioma / blood supply. Meningioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Arteriovenous Malformations / diagnosis. Brain Neoplasms / diagnosis. Calcinosis / diagnosis. Calcinosis / pathology. Child. Contrast Media. Diagnosis, Differential. Diagnostic Errors. Female. Glioma / diagnosis. Humans. Image Enhancement / methods. Magnetic Resonance Imaging. Male. Retrospective Studies. Tomography, X-Ray Computed. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19820515.001).
  • [ISSN] 1532-3145
  • [Journal-full-title] Journal of computer assisted tomography
  • [ISO-abbreviation] J Comput Assist Tomogr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


28. Degaki TL, Demasi MA, Sogayar MC: Overexpression of Nrp/b (nuclear restrict protein in brain) suppresses the malignant phenotype in the C6/ST1 glioma cell line. J Steroid Biochem Mol Biol; 2009 Nov;117(4-5):107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of Nrp/b (nuclear restrict protein in brain) suppresses the malignant phenotype in the C6/ST1 glioma cell line.
  • Upon searching for glucocorticoid-regulated cDNA sequences associated with the transformed to normal phenotypic reversion of C6/ST1 rat glioma cells, we identified Nrp/b (nuclear restrict protein in brain) as a novel rat gene.
  • Among rat tissues, Nrp/b expression is more pronounced in brain tissue.
  • We show that overexpression of the Nrp/b cDNA in C6/ST1 cells suppresses anchorage independence in vitro and tumorigenicity in vivo, altering their malignant nature towards a more benign phenotype.
  • Therefore, Nrp/b may be postulated as a novel tumor suppressor gene, with possible relevance for glioblastoma therapy.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Microfilament Proteins / genetics. Neuropeptides / genetics. Nuclear Proteins / genetics
  • [MeSH-minor] Amino Acid Sequence. Animals. Base Sequence. Blotting, Western. Cell Line, Tumor. Cloning, Molecular. DNA, Complementary. Gene Expression Regulation. Humans. Immunohistochemistry. Molecular Sequence Data. Rats. Sequence Homology, Amino Acid

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19682578.001).
  • [ISSN] 1879-1220
  • [Journal-full-title] The Journal of steroid biochemistry and molecular biology
  • [ISO-abbreviation] J. Steroid Biochem. Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Microfilament Proteins; 0 / Neuropeptides; 0 / Nuclear Proteins; 0 / ectodermal-neural cortex 1 protein
  •  go-up   go-down


29. Hohenstein C, Herdtle S: Unexpected death from a colloid cyst. Int J Emerg Med; 2010;3(1):65-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Colloid cysts are usually benign brain tumors, which rarely cause acute neurological deterioration with sudden death due to an acute increase of intracranial pressure.
  • CONCLUSION: Subtle distinctions between symptoms due to intracranial hypertension, which typically cause headache and vomiting, and true gastroenteritis are discussed as well as the pathophysiology of neurogenic pulmonary edema and the origin of cerebral-triggered cardiac dysrhythmias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):392-5 [8869070.001]
  • [Cites] Ann Emerg Med. 1997 Apr;29(4):524-8 [9095015.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):367-70 [12140107.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):305-9 [16180045.001]
  • [Cites] J Clin Neurosci. 1995 Oct;2(4):307-11 [18638833.001]
  • [Cites] Acta Anaesthesiol Scand. 2007 Apr;51(4):447-55 [17378783.001]
  • [Cites] Physiol Res. 2008;57(4):499-506 [18052674.001]
  • [Cites] Am J Forensic Med Pathol. 2008 Jun;29(2):170-2 [18520488.001]
  • [Cites] Pediatr Cardiol. 2006 Mar-Apr;27(2):286-8 [16463127.001]
  • (PMID = 20414387.001).
  • [ISSN] 1865-1380
  • [Journal-full-title] International journal of emergency medicine
  • [ISO-abbreviation] Int J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2850975
  • [Keywords] NOTNLM ; Cardiopulmonary complication / Colloid cyst / Unexpected death
  •  go-up   go-down


30. Harada M, Ishihara Y, Itoh K, Yamanaka R: Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T lymphocytes in human leukocyte antigen-A24+ glioma patients. Oncol Rep; 2007 Mar;17(3):629-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we searched for new target candidates in specific immunotherapy for malignant glioma by utilizing cDNA microarray technology to compare gene expressions in malignant glioma tissues to those in benign glioma and a panel of normal tissues.
  • [MeSH-major] Antigens, Neoplasm / isolation & purification. Brain Neoplasms / immunology. Glioma / immunology. HLA-A Antigens / immunology. Kinesin / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Cancer Vaccines. Cell Line, Tumor. Gene Expression. Gene Expression Profiling. HLA-A24 Antigen. Humans. Immunoglobulin G / blood. Immunoglobulin G / immunology. Immunotherapy / methods. Oligonucleotide Array Sequence Analysis. Peptides / immunology. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273744.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / HLA-A Antigens; 0 / HLA-A24 Antigen; 0 / Immunoglobulin G; 0 / Peptides; 0 / RNA, Messenger; EC 3.6.1.- / Kinesin
  •  go-up   go-down


31. Lee GC, Choi SW, Kim SH, Kwon HJ: Multiple extracranial metastases of atypical meningiomas. J Korean Neurosurg Soc; 2009 Feb;45(2):107-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas are usually benign neoplasms in which extracranial metastases occur very rarely.
  • A computed tomography (CT) scan and magnetic resonance imaging (MRI) showed an intraventricular tumor.
  • We performed a total mass removal, and the histopathologic findings were consistent with benign meningioma.
  • We performed a reoperation and whole brain radiation therapy postoperatively.
  • The histopathologic findings of the spinal tumors showed atypical meningioma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2008;204(5):305-14 [18374497.001]
  • [Cites] Spine (Phila Pa 1976). 2000 Mar 15;25(6):727-31 [10752106.001]
  • [Cites] J Neurosurg. 1964 Dec;21:1098-102 [14281384.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Dec;23(6):496-506 [9460716.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Oncology (Williston Park). 1996 May;10(5):747-56; discussion 756-9 [8738830.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(10):1172-7; discussion 1177-8 [8955436.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):478-82 [2915253.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] AJNR Am J Neuroradiol. 1982 May-Jun;3(3):267-76 [6805276.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Cancer. 1970 Oct;26(4):832-41 [5528265.001]
  • [Cites] Anticancer Drugs. 2003 Mar;14(3):247-50 [12634620.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):36-40 [16220350.001]
  • (PMID = 19274122.001).
  • [ISSN] 2005-3711
  • [Journal-full-title] Journal of Korean Neurosurgical Society
  • [ISO-abbreviation] J Korean Neurosurg Soc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2651555
  • [Keywords] NOTNLM ; Anaplastic meningioma / Atypical meningioma / Extracranial metastasis
  •  go-up   go-down


32. Pandita A, Balasubramaniam A, Perrin R, Shannon P, Guha A: Malignant and benign ganglioglioma: a pathological and molecular study. Neuro Oncol; 2007 Apr;9(2):124-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant and benign ganglioglioma: a pathological and molecular study.
  • Gangliogliomas are generally benign tumors, composed of transformed neuronal and glial elements, with rare malignant progression of the glial component.
  • Conventional and array comparative genomic hybridization (approximately 2.5-Mb resolution) analyses found chromosomal losses to be predominant in the benign areas of the ganglioglioma, with gains more prevalent in the malignant component.
  • Deciphering the specific genes residing in these chromosomal regions may further our understanding of not only these rare tumors but also the more common gliomas.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Ganglioglioma / genetics. Ganglioglioma / pathology
  • [MeSH-minor] Adult. Chromosome Mapping. DNA, Neoplasm / genetics. DNA, Neoplasm / isolation & purification. Female. Genes, p16. Genes, p53. Humans. Oligonucleotide Array Sequence Analysis. Receptors, Androgen / genetics. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ganglioglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Genome Res. 2004;107(1-2):77-82 [15305059.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):262-75 [10935481.001]
  • [Cites] Neurosurgery. 1983 Aug;13(2):124-8 [6888690.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):501-8 [7856759.001]
  • [Cites] Am J Pathol. 1995 Mar;146(3):613-9 [7887443.001]
  • [Cites] Nucleic Acids Res. 1995 Apr 25;23(8):1411-8 [7753634.001]
  • [Cites] Cancer Res. 1995 Nov 1;55(21):5080-4 [7585555.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):150-3 [8548755.001]
  • [Cites] J Neuropathol Exp Neurol. 1996 Jul;55(7):822-31 [8965097.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):565-71 [9250169.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Br J Cancer. 1999 Aug;80(12):2034-9 [10471057.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):41-6 [10471496.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):69-73 [15860361.001]
  • [Cites] J Neurooncol. 2005 Apr;72(2):103-6 [15925988.001]
  • [Cites] Adv Cancer Res. 2005;94:1-27 [16095998.001]
  • [Cites] Am J Dermatopathol. 2005 Aug;27(4):279-85 [16121045.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6177-85 [16144918.001]
  • [Cites] Lab Invest. 2001 May;81(5):717-23 [11351043.001]
  • [Cites] J Neurosurg. 2001 Jul;95(1):138-42 [11453385.001]
  • [Cites] Cancer Res. 2001 Aug 1;61(15):5895-904 [11479231.001]
  • [Cites] Am J Pathol. 2002 Sep;161(3):807-12 [12213708.001]
  • [Cites] Neoplasia. 2003 Jan-Feb;5(1):53-62 [12659670.001]
  • [Cites] Pathol Int. 2003 Dec;53(12):874-82 [14629754.001]
  • [Cites] Int J Oncol. 2006 Mar;28(3):667-74 [16465372.001]
  • [Cites] Breast Cancer Res. 2006;8(1):R9 [16417655.001]
  • [Cites] Oncogene. 2006 Mar 9;25(10):1571-83 [16247447.001]
  • [Cites] J Neurosurg. 1981 Jan;54(1):58-63 [7463121.001]
  • (PMID = 17259542.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Receptors, Androgen
  • [Other-IDs] NLM/ PMC1871674
  •  go-up   go-down


33. Monfared A, Agrawal S, Jackler RK: Cranial base approaches to inaccessible intracranial tumors. Curr Opin Neurol; 2007 Dec;20(6):726-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cranial base approaches to inaccessible intracranial tumors.
  • PURPOSE OF REVIEW: Craniotomy created through the base of the skull has improved exposure of many types of extraaxial tumors and thus enhanced both tumor control and preservation of neural function.
  • The increasingly documented efficacy of stereotactic radiation for certain tumor types (e.g. meningioma, schwannoma) has permitted nonoperative therapy for some individuals.
  • In large tumors, selective use of less-than-complete microsurgical resection is establishing an increasing role, at times combined with focused radiotherapy of the surgical remnant.
  • The role for transbasal craniotomy is well established in both benign tumors and vascular lesions, but has only limited applicability for high-grade malignant lesions.
  • [MeSH-major] Brain Neoplasms / surgery. Craniotomy / methods. Neurosurgical Procedures / methods. Postoperative Complications / prevention & control. Skull Base / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17992097.001).
  • [ISSN] 1350-7540
  • [Journal-full-title] Current opinion in neurology
  • [ISO-abbreviation] Curr. Opin. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 55
  •  go-up   go-down


34. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol; 2006 Aug;27(7):1432-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
  • BACKGROUND AND PURPOSE: [(11)C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy.
  • METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B).
  • Semiquantitative methionine uptake indices (UI) defined by the tumor (maximum)-to-background ratio was correlated with tumor grade and final outcome.
  • Although a weak linear correlation between MET uptake and grading was observed (R = 0.38, P = .028), analysis of variance showed no significant differences in MET UI between tumor grades for either group A or B.
  • Benign and grade I lesions showed significant difference in MET uptake in comparison with higher grade lesions (P = .006).
  • Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Brain / metabolism. Child. Child, Preschool. Disease Progression. Female. Forecasting. Humans. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908552.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


35. Arai A, Sasayama T, Tamaki M, Sakagami Y, Enoki E, Ohbayashi C, Kohmura E: Rosette-forming glioneuronal tumor of the fourth ventricle--case report. Neurol Med Chir (Tokyo); 2010;50(3):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosette-forming glioneuronal tumor of the fourth ventricle--case report.
  • Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare tumor included as a novel glioneuronal neoplasm in the 2007 World Health Organization classification of brain tumors.
  • The tumor was gross totally resected.
  • RGNT of the fourth ventricle should be considered in the differential diagnosis of infratentorial lesions in young adults.
  • The prognosis is benign, but relatively aggressive behaviors such as tumor growth, recurrence, and acute deterioration due to intratumoral hemorrhaging can occur.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology. Infratentorial Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339273.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Allan R, Chaseling R, Graf N, Dexter M: Aqueduct stenosis-?Benign. J Clin Neurosci; 2005 Feb;12(2):178-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aqueduct stenosis-?Benign.
  • 'Benign' aqueduct stenosis is a common cause of hydrocephalus in the paediatric population and is frequently treated by endoscopic third ventriculostomy.
  • The case histories are presented, along with the recommendation for increased radiological screening of patients with this usually 'benign' presentation.
  • [MeSH-major] Brain Neoplasms / complications. Cerebral Aqueduct / pathology. Pineal Gland / pathology. Pinealoma / complications

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15749425.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


37. Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C: [Histological and molecular classification of gliomas]. Rev Neurol (Paris); 2008 Jun-Jul;164(6-7):505-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Classification histologique et moléculaire des gliomes.
  • Gliomas are the most frequent tumors of the central nervous system.
  • The main histological subtype of grade I gliomas are pilocytic astrocytomas, which are benign.
  • Diffuse astrocytomas, oligodendrogliomas and oligoastrocytomas are low-grade (II) or high-grade (III and IV) tumors.
  • Daumas-Duport et al. have proposed another classification based on histology and imaging data, which distinguishes oligodendrogliomas and mixed gliomas of grade A (without endothelial proliferation and/or contrast enhancement), oligodendrogliomas and mixed gliomas of grade B (with endothelial proliferation or contrast enhancement), glioblastomas and glioneuronal malignant tumors.
  • De novo glioblastomas, which occur in young patients without of a prior history of brain tumor and harbor frequent amplification of EGFR, deletion of p16 and mutation of PTEN while mutation of p53 is infrequent.
  • However, histological and molecular classifications do not always correspond as many alterations are shared by high-grade tumors, whatever their histological type.
  • [MeSH-major] Brain Neoplasms / pathology. Glioma / pathology


38. Witek-Janusek L, Gabram S, Mathews HL: Psychologic stress, reduced NK cell activity, and cytokine dysregulation in women experiencing diagnostic breast biopsy. Psychoneuroendocrinology; 2007 Jan;32(1):22-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Psychological assessments demonstrated that perceived stress, anxiety, and mood disturbance were heightened before biopsy and remained elevated after biopsy regardless of the diagnosis.
  • These results demonstrate that undergoing biopsy of the breast for cancer diagnosis is an emotional experience, characterized by increased perceived stress, anxiety, and mood disturbance.
  • Noteworthy is the observation that women with benign or malignant biopsy results experienced similar psycho-immune consequences.
  • Hence, these observations are of relevance not only to women diagnosed with malignancy, who face the challenges of cancer treatment and adaptation to illness, but also to women with benign biopsy findings.

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stress.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Health Psychol. 1994 Jul;13(4):291-8 [7957007.001]
  • [Cites] Blood. 1995 Jan 1;85(1):57-65 [7528573.001]
  • [Cites] Physiol Rev. 1995 Jan;75(1):77-106 [7831399.001]
  • [Cites] Oncol Nurs Forum. 1994 Nov-Dec;21(10):1723-7 [7854934.001]
  • [Cites] Cancer Pract. 1994 Jul-Aug;2(4):288-96 [7858656.001]
  • [Cites] J Neuroimmunol. 1995 Jun;59(1-2):83-9 [7797623.001]
  • [Cites] Nurs Res. 1995 Jul-Aug;44(4):196-201 [7624228.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 Mar;1(2):125-33 [7496932.001]
  • [Cites] Psychosom Med. 1996 May-Jun;58(3):264-72 [8771626.001]
  • [Cites] Nat Immunol. 2004 Dec;5(12):1260-5 [15531883.001]
  • [Cites] Brain Behav Immun. 2005 Jan;19(1):3-11 [15581732.001]
  • [Cites] Annu Rev Physiol. 2005;67:259-84 [15709959.001]
  • [Cites] Ann N Y Acad Sci. 2000;917:38-67 [11268364.001]
  • [Cites] Nat Immunol. 2001 Jan;2(1):23-7 [11135574.001]
  • [Cites] J Interferon Cytokine Res. 2001 Mar;21(3):147-55 [11331037.001]
  • [Cites] Blood. 2001 May 15;97(10):3146-51 [11342442.001]
  • [Cites] Trends Immunol. 2001 Nov;22(11):633-40 [11698225.001]
  • [Cites] J Clin Nurs. 2001 Jul;10(4):512-20 [11822499.001]
  • [Cites] J Immunol. 1989 Nov 15;143(10):3183-91 [2530273.001]
  • [Cites] Adv Immunol. 1989;47:187-376 [2683611.001]
  • [Cites] J Exp Med. 1990 Apr 1;171(4):979-96 [2139106.001]
  • [Cites] Arch Gen Psychiatry. 1990 Aug;47(8):729-35 [2143062.001]
  • [Cites] Circulation. 1990 Dec;82(6):2003-10 [2173645.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2421-38 [2265240.001]
  • [Cites] Psychosom Med. 1991 Mar-Apr;53(2):121-32 [2031066.001]
  • [Cites] Neuropsychobiology. 1993;28(1-2):87-90 [8255416.001]
  • [Cites] Nat Immun. 1993 Jul-Oct;12(4-5):279-92 [8257832.001]
  • [Cites] Psychosom Med. 1993 Sep-Oct;55(5):395-409 [8265740.001]
  • [Cites] Am Psychol. 1994 May;49(5):389-404 [8024167.001]
  • [Cites] Cancer. 1994 Aug 15;74(4 Suppl):1484-95 [8062180.001]
  • [Cites] Immunol Today. 1994 Jul;15(7):301-3 [8086097.001]
  • [Cites] J Exp Med. 1996 Nov 1;184(5):1781-90 [8920866.001]
  • [Cites] Brain Res Brain Res Rev. 1997 Feb;23(1-2):79-133 [9063588.001]
  • [Cites] Nat Immun. 1996-1997;15(2-3):107-16 [9162261.001]
  • [Cites] Nat Immun. 1996-1997;15(2-3):117-33 [9162262.001]
  • [Cites] J Med Screen. 1997;4(3):158-68 [9368874.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):30-6 [9428780.001]
  • [Cites] Cancer Nurs. 1998 Apr;21(2):117-26 [9556938.001]
  • [Cites] J Public Health Med. 1998 Dec;20(4):396-403 [9923945.001]
  • [Cites] Pediatr Res. 1999 Feb;45(2):224-9 [10022594.001]
  • [Cites] Brain Behav Immun. 1998 Dec;12(4):297-307 [10080859.001]
  • [Cites] Biol Psychiatry. 1999 Apr 1;45(7):833-9 [10202570.001]
  • [Cites] Annu Rev Immunol. 1999;17:189-220 [10358757.001]
  • [Cites] Curr Opin Microbiol. 1999 Aug;2(4):374-81 [10458991.001]
  • [Cites] J Public Health Med. 2001 Dec;23(4):292-300 [11873891.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;966:290-303 [12114286.001]
  • [Cites] Health Psychol. 2002 Sep;21(5):485-94 [12211516.001]
  • [Cites] Immunol Rev. 2002 Oct;188:9-21 [12445277.001]
  • [Cites] J Behav Med. 2003 Apr;26(2):153-64 [12776384.001]
  • [Cites] J Psychiatr Ment Health Nurs. 2003 Aug;10(4):401-9 [12887631.001]
  • [Cites] J Psychosom Res. 2003 Nov;55(5):437-43 [14581098.001]
  • [Cites] Trends Immunol. 2003 Nov;24(11):603-9 [14596885.001]
  • [Cites] Neuro Endocrinol Lett. 2003 Oct;24(5):283-92 [14646999.001]
  • [Cites] Annu Rev Immunol. 2004;22:745-63 [15032595.001]
  • [Cites] J Natl Cancer Inst. 2004 Apr 7;96(7):529-38 [15069115.001]
  • [Cites] Psychol Bull. 2004 Jul;130(4):601-30 [15250815.001]
  • [Cites] Ann N Y Acad Sci. 2004 Jun;1024:138-46 [15265778.001]
  • [Cites] Int J Cancer. 1980 Jan 15;25(1):9-17 [6447114.001]
  • [Cites] Ann N Y Acad Sci. 1980;350:121-9 [6165267.001]
  • [Cites] J Immunol. 1983 Feb;130(2):768-72 [6184405.001]
  • [Cites] J Health Soc Behav. 1983 Dec;24(4):385-96 [6668417.001]
  • [Cites] J Behav Med. 1986 Feb;9(1):5-21 [2939253.001]
  • [Cites] J Immunol. 1986 Jun 15;136(12):4480-6 [3086432.001]
  • [Cites] J Immunol. 1986 Dec 15;137(12):3845-54 [3491151.001]
  • [Cites] J Clin Oncol. 1987 Mar;5(3):348-53 [3546612.001]
  • [Cites] Am J Psychiatry. 1987 Apr;144(4):437-41 [2952025.001]
  • [Cites] Psychosom Med. 1987 Sep-Oct;49(5):523-35 [3671639.001]
  • [Cites] J Psychosom Res. 1988;32(2):173-80 [3404499.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5808-13 [15817686.001]
  • [Cites] Psychosom Med. 2005 May-Jun;67(3):366-75 [15911898.001]
  • [Cites] Arch Intern Med. 2005 Jul 25;165(14):1593-8 [16043676.001]
  • [Cites] Brain Behav Immun. 1996 Jun;10(2):77-91 [8811932.001]
  • [Cites] J Exp Med. 1999 Nov 1;190(9):1297-308 [10544201.001]
  • [Cites] Eur J Immunol. 2000 Jul;30(7):1823-9 [10940871.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1261-7 [11044347.001]
  • [Cites] Blood. 2001 Jan 1;97(1):192-7 [11133760.001]
  • [Cites] Brain Behav Immun. 2001 Mar;15(1):78-84 [11259082.001]
  • [Cites] Psychosom Med. 1991 Jul-Aug;53(4):345-62 [1656478.001]
  • [Cites] Health Care Women Int. 1992 Jan-Mar;13(1):23-32 [1556029.001]
  • [Cites] Psychol Bull. 1992 May;111(3):475-89 [1594722.001]
  • [Cites] Circulation. 1992 Jul;86(1):203-13 [1319854.001]
  • [Cites] Psychosom Med. 1992 Jul-Aug;54(4):394-406 [1502282.001]
  • [Cites] Int J Sports Med. 1992 Jul;13(5):359-66 [1325959.001]
  • [Cites] J Immunol. 1992 Nov 1;149(9):2977-83 [1401925.001]
  • [Cites] J Exp Med. 1993 Apr 1;177(4):1199-204 [8096238.001]
  • [Cites] J Interferon Res. 1993 Aug;13(4):247-57 [7693829.001]
  • (PMID = 17092654.001).
  • [ISSN] 0306-4530
  • [Journal-full-title] Psychoneuroendocrinology
  • [ISO-abbreviation] Psychoneuroendocrinology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA117261-02; United States / NCI NIH HHS / CA / R01 CA134736-02; United States / NCI NIH HHS / CA / R01 CA125455; United States / NCI NIH HHS / CA / R03 CA077120-01; United States / NCI NIH HHS / CA / R21 CA117261-02; United States / NCI NIH HHS / CA / R03 CA072848-01; United States / NCI NIH HHS / CA / R01 CA134736; United States / NCI NIH HHS / CA / CA-77120; United States / NCI NIH HHS / CA / R21 CA117261
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  • [Other-IDs] NLM/ NIHMS16388; NLM/ PMC3937868
  •  go-up   go-down


39. Qaddoumi I, Sultan I, Broniscer A: Pediatric low-grade gliomas and the need for new options for therapy: Why and how? Cancer Biol Ther; 2009 Jan;8(1):4-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pediatric low-grade gliomas are the most common tumors of the central nervous system in children, accounting for almost 50% of all childhood brain tumors.
  • They are a heterogeneous group of tumors with different histologic subtypes.
  • This is mostly due to a lack of understanding of tumor biology at the molecular level.
  • Pediatric low-grade gliomas are not benign, and most incompletely resected tumors will progress and negatively affect quality of life.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neuropathol. 1993;86(1):81-5 [8103960.001]
  • [Cites] J Neurosurg. 1994 Jul;81(1):24-30 [8207524.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Mar;12(3):165-72 [7536455.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):67-71 [7782852.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):979-86 [7672798.001]
  • [Cites] Acta Neuropathol. 1995;90(3):319-22 [8525807.001]
  • [Cites] J Pediatr. 1995 Nov;127(5):718-22 [7472822.001]
  • [Cites] Ann Neurol. 1997 Feb;41(2):143-9 [9029062.001]
  • [Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Cancer Genet Cytogenet. 1997 Aug;97(1):39-53 [9242217.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] Childs Nerv Syst. 1997 Oct;13(10):550-5 [9403205.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jul 15;104(2):157-60 [9666811.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jan;58(1):46-53 [10068313.001]
  • [Cites] J Neurosurg. 1999 Apr;90(2 Suppl):231-3 [10199253.001]
  • [Cites] Eur J Hum Genet. 1999 Apr;7(3):267-73 [10234502.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Klin Padiatr. 2004 Nov-Dec;216(6):331-42 [15565548.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):236-45 [15665300.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2755-60 [15805275.001]
  • [Cites] Curr Biol. 2005 Apr 26;15(8):702-13 [15854902.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2636-42 [15861409.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7429-35 [16103096.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Oct;31(5):556-60 [16150126.001]
  • [Cites] Neurology. 2005 Oct 25;65(8):1335-6 [16247081.001]
  • [Cites] J Neurosurg. 2005 Oct;103(4 Suppl):357-61 [16270688.001]
  • [Cites] J Neurooncol. 2005 Dec;75(3):301-7 [16195800.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Sep;59(9):759-67 [11005256.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] Pediatr Neurosurg. 2001 May;34(5):229-34 [11423771.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Childs Nerv Syst. 2001 Sep;17(9):503-11 [11585322.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902 [12387455.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:a1-9 [12456321.001]
  • [Cites] J Neurosurg. 2002 Dec;97(6):1350-5 [12507133.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Childs Nerv Syst. 2003 Apr;19(4):197-203 [12682758.001]
  • [Cites] Neuro Oncol. 2003 Jul;5(3):188-96 [12816725.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1807-16 [16809032.001]
  • [Cites] Neuropathology. 2006 Oct;26(5):442-6 [17080723.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1049-58 [17086101.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):682-9 [17308273.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):161-8 [17347491.001]
  • [Cites] Ann Neurol. 2007 Mar;61(3):189-98 [17387725.001]
  • [Cites] Histol Histopathol. 2007 Aug;22(8):895-903 [17503347.001]
  • [Cites] Neuropediatrics. 2007 Apr;38(2):61-3 [17712732.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1243-52 [12973849.001]
  • [Cites] Am J Hum Genet. 2003 Nov;73(5):1191-8 [14566704.001]
  • [Cites] Br J Neurosurg. 2003 Aug;17(4):327-35 [14579898.001]
  • [Cites] Neurol Res. 2003 Oct;25(7):691-3 [14579783.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4572-8 [14673044.001]
  • [Cites] Neurology. 2006 Jan 10;66(1):127-30 [16401863.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):396-402 [16353203.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):377-80 [15800886.001]
  • [Cites] Ann Neurol. 2006 Mar;59(3):490-8 [16453317.001]
  • [Cites] Neoplasia. 2006 Feb;8(2):136-42 [16611406.001]
  • [Cites] Cancer Cell. 2006 May;9(5):341-9 [16697955.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] J Neurosurg. 2006 May;104(5 Suppl):314-20 [16848088.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):430-7 [17704361.001]
  • [Cites] Br J Ophthalmol. 2008 Jan;92(1):40-6 [17962395.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1784(1):116-32 [17913600.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):892-9 [18098210.001]
  • [Cites] Cancer Res. 2008 Mar 1;68(5):1520-8 [18316617.001]
  • [Cites] Methods Enzymol. 2008;438:307-20 [18413257.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2139-46 [18390968.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Rev Recent Clin Trials. 2007 May;2(2):121-34 [18473997.001]
  • [Cites] Brain Pathol. 2008 Jul;18(3):326-37 [18371186.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):324-8 [18504420.001]
  • [Cites] Pediatr Neurosurg. 2008;44(4):333-6 [18552517.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] PLoS One. 2008;3(8):e3065 [18725974.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] J Clin Oncol. 2012 Apr 20;30(12):1358-63 [22393086.001]
  • [Cites] Recent Pat Antiinfect Drug Discov. 2006 Jun;1(2):241-6 [18221149.001]
  • [Cites] Radiother Oncol. 2000 Mar;54(3):239-45 [10738082.001]
  • [Cites] Clin Neuropathol. 2000 Mar-Apr;19(2):57-62 [10749285.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):722-5 [10761668.001]
  • [Cites] Int J Hematol. 2003 Dec;78(5):383-9 [14704030.001]
  • [Cites] Cancer Cell. 2004 Oct;6(4):313-9 [15488754.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):862-6 [4056900.001]
  • [Cites] Neurosurgery. 1988 Nov;23(5):545-56 [3143922.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(21):8323-7 [2682646.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):45-52 [2104571.001]
  • [Cites] Cell. 1990 Aug 10;62(3):599-608 [2116237.001]
  • [Cites] J Neurosurg. 1992 Aug;77(2):302-6 [1625019.001]
  • [Cites] Pediatr Neurosurg. 1992;18(4):207-17 [1472434.001]
  • (PMID = 19164945.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; None / None / / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA021765-31; United States / NCI NIH HHS / CA / P30 CA21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Number-of-references] 97
  • [Other-IDs] NLM/ NIHMS161402; NLM/ PMC2810626
  •  go-up   go-down


40. Kita T, Hayashi K, Yamamoto M, Kawauchi T, Sakata I, Iwasaki Y, Kosuda S: Does supplementation of contrast MR imaging with thallium-201 brain SPECT improve differentiation between benign and malignant ring-like contrast-enhanced cerebral lesions? Ann Nucl Med; 2007 Jul;21(5):251-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does supplementation of contrast MR imaging with thallium-201 brain SPECT improve differentiation between benign and malignant ring-like contrast-enhanced cerebral lesions?
  • OBJECTIVE: To determine whether thallium-201 ((201)Tl) brain single photon emission computed tomography (SPECT) could supplement magnetic resonance (MR) imaging diagnostic information by visual comparison of two separate data sets from patients with ring-like contrast-enhanced cerebral lesions.
  • METHODS: A combination of MR imaging and (201)Tl brain SPECT sets obtained from 13 patients (10 men, 3 women) ranging in age from 26 years to 86 years (mean 61.0 years) were retrospectively reviewed.
  • The final diagnoses were six glioblastomas, two cerebral metastases from lung cancer, and one each of abscess, resolving hematoma, primary central nervous system lymphoma, toxoplasmosis, and radiation necrosis.
  • Images were scored in terms of how benign or malignant the foci were on a 5-point scale from "definitely benign" to "definitely malignant."
  • RESULTS: The improvement in the performance of all ten readers was from 67.7% to 93.8% in mean accuracy (P = 0.0028) and from 0.730 to 0.971 in mean Az value (P = 0.0069) after they were shown the (201)Tl brain SPECT images.
  • CONCLUSIONS: (201)Tl brain SPECT should substantially increase confidence in the diagnosis of intracranial lesions with ring-like contrast enhancement when MR imaging does not permit differentiation between benign and malignant disease.
  • [MeSH-major] Brain / radionuclide imaging. Contrast Media / pharmacology. Thallium Radioisotopes / pharmacology. Tomography, Emission-Computed, Single-Photon / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / diagnosis. Brain Neoplasms / radionuclide imaging. Female. Humans. Image Processing, Computer-Assisted. Magnetic Resonance Imaging / methods. Male. Middle Aged. Reproducibility of Results

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17634842.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Thallium Radioisotopes
  •  go-up   go-down


41. Rousseau A, Kujas M, van Effenterre R, Boch AL, Carpentier A, Leroy JP, Poirier J: Primary intracranial myopericytoma: report of three cases and review of the literature. Neuropathol Appl Neurobiol; 2005 Dec;31(6):641-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Myopericytoma is a benign tumour generally arising in the subcutaneous and superficial soft tissues of the extremities.
  • The tumour involved, respectively, the anterior cranial fossa, the orbital apex and the pineal region.
  • Myopericytoma is a recently described neoplasm, and it is likely that reappraisal of intracranial haemangiopericytoma with which it shares many histopathologic features will lead to more case reports of primary intracranial myopericytoma.
  • [MeSH-major] Brain Neoplasms / pathology. Hemangiopericytoma / pathology. Myofibromatosis / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16281913.001).
  • [ISSN] 0305-1846
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 24
  •  go-up   go-down


42. Liu J, Zheng S, Yu JK, Yu XB, Liu WG, Zhang JM, Hu X: [Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar;34(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy-five samples of cerebrospinal fluid from patients with gliomas, benign brain tumors and mild brain traumas were collected.
  • A total of 50 samples from gliomas and non-brain-tumors were divided into training sets (33 cases including 17 gliomas and 16 non-brain-tumors) and testing sets (17 cases including 5 gliomas and 12 non-brain-tumors).
  • The cerebrospinal proteins bound to H4 chip were detected by SELDI-TOF MS, the profiles of cerebrospinal protein were gained and then analyzed with artificial neural network algorithm (ANN); and the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established.
  • Forty-seven of cerebrospinal samples of gliomas and benign brain tumors were divided into training sets (31 cases including 13 gliomas and 18 benign brain tumors) and testing sets (16 cases including 9 gliomas and 7 benign brain tumors), the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from benign brain tumors was established based on the same method.
  • RESULT: The diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established and was challenged with the test set randomly, the sensitivity and specificity were 100% and 91.7%, respectively.
  • The cerebrospinal protein profiling model for differentiating gliomas from benign brain tumors was also developed and was challenged with the test set randomly, the sensitivity and specificity were 88.9%, and 100%, respectively.
  • CONCLUSION: The technology of SELDI-TOF MS which combined with analysis tools of bioinformatics is a novel effective method for screening and identifying tumor biomarkers of gliomas and it may provide a new approach for the clinical diagnosis of glioma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Cerebrospinal Fluid Proteins / genetics. Glioma / cerebrospinal fluid. Peptide Mapping / standards
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Male. Meningioma / cerebrospinal fluid. Meningioma / diagnosis. Middle Aged. Neural Networks (Computer). Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812888.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cerebrospinal Fluid Proteins
  •  go-up   go-down


43. Melamed I, Merkin V, Korn A, Nash M: The supraorbital approach: an alternative to traditional exposure for the surgical management of anterior fossa and parasellar pathology. Minim Invasive Neurosurg; 2005 Oct;48(5):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Included were benign and malignant tumors, AVM, tuberculoma and trauma.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain Neoplasms / pathology. Brain Neoplasms / radiography. Brain Neoplasms / surgery. Craniocerebral Trauma / pathology. Craniocerebral Trauma / surgery. Female. Humans. Intracranial Arteriovenous Malformations / radiography. Intracranial Arteriovenous Malformations / surgery. Male. Middle Aged. Skull Base / radiography. Skull Base / surgery. Treatment Outcome. Tuberculoma / pathology. Tuberculoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16320185.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Asanuma K, Kasai Y, Takegami K, Ito H, Yoshikawa T, Uchida A: Spinal neurocutaneous melanosis without cutaneous nevi. Spine (Phila Pa 1976); 2008 Oct 1;33(21):E798-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To show a case and review the epidemiology, diagnosis and treatment of neurocutaneous melanosis without cutaneous nevi.
  • SUMMARY OF BACKGROUND DATA: Neurocutaneous melanosis is a rare congenital syndrome consisting of benign or malignant melanocytic tumors of the central nervous system and cutaneous nevi.
  • In general, patients are treated with palliative therapy, such as shunt placement to reduce intracranial pressure or tumor resection to reduce compression of the brain or spine.
  • Magnetic resonance imaging (MRI) of the spine revealed intradural tumor at the T5 level.
  • Computed tomography myelography showed intradural extramedullary tumor.
  • After the pigmented dura was opened, a pigmented tumor was resected.
  • RESULTS: Histologically, the pigmented tumor represented low grade.
  • The pigmented dura and bone comprised melanin-bearing cells without tumor cells.
  • The diagnosis in this case was speculated to represent a forme fruste of neurocutaneous melanosis.
  • [MeSH-major] Melanosis / radiography. Meningeal Neoplasms / radiography. Neurocutaneous Syndromes / radiography
  • [MeSH-minor] Adult. Humans. Male. Nevus, Intradermal / radiography. Nevus, Intradermal / surgery. Skin Neoplasms / radiography. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Neurocutaneous melanosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827686.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Grund S, Schittenhelm J, Roser F, Tatagiba M, Mawrin C, Kim YJ, Bornemann A: The microglial/macrophagic response at the tumour-brain border of invasive meningiomas. Neuropathol Appl Neurobiol; 2009 Feb;35(1):82-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The microglial/macrophagic response at the tumour-brain border of invasive meningiomas.
  • AIMS: Little is known about the immune response of the brain to invasive meningiomas.
  • The present study was based upon the hypothesis that the microglial/macrophagic response towards brain-invasive meningiomas is dependent on the intactness of the pial-glial basement membrane.
  • METHODS: We immunostained sections from 40 brain-invasive meningiomas that were graded according to World Health Organization (WHO) 2007 criteria.
  • Thirty-three tumours were histologically WHO grade II (18, 'otherwise benign', and 15, 'otherwise atypical'), and seven, grade III.
  • RESULTS: Twenty-five per cent (10/40) meningiomas (1/18 WHO grade II 'otherwise benign', 3/15 grade II 'otherwise atypical' and 6/7 WHO grade III) contained microglial/macrophagic cells at the tumour-brain border.
  • The monocytic response was of two kinds: one consisted of a dense layer of mononuclear cells at the tumour-brain border in nine cases, the other of an elevated number of microglial cells expressing CD14 or CD163 (two cases).
  • CONCLUSIONS: The immune response at the tumour-brain interface correlates with the absence of the pial-glial BM and with malignancy grade.
  • It remains to be established whether the mononuclear cells at the tumour-brain border are native microglia or blood-derived macrophages.
  • [MeSH-major] Brain / immunology. Brain Neoplasms / immunology. Macrophages / immunology. Meningioma / immunology. Microglia / immunology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187060.001).
  • [ISSN] 1365-2990
  • [Journal-full-title] Neuropathology and applied neurobiology
  • [ISO-abbreviation] Neuropathol. Appl. Neurobiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD14; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / CD68 antigen, human; 0 / Receptors, Cell Surface
  •  go-up   go-down


46. Broekman ML, Risselada R, Engelen-Lee J, Spliet WG, Verweij BH: Glioblastoma multiforme in the posterior cranial fossa in a patient with neurofibromatosis type I. Case Rep Med; 2009;2009:757898
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with Neurofibromatosis type 1 (NF1) have an increased risk of developing neoplasms.
  • The most common brain tumors, found in 15%-20% of NF1 patients, are hypothalamic-optic gliomas, followed by brainstem and cerebellar pilocytic astrocytomas.
  • These tumors generally have a benign nature.
  • NF1 patients are predisposed to a 5-fold increased incidence of high-grade astrocytomas, which are usually located in supratentorial regions of the brain.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Med Genet. 1999 Dec;36(12):893-6 [10593996.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] J Biol Chem. 2005 Oct 14;280(41):34924-32 [16079146.001]
  • [Cites] Cancer Cell. 2005 Aug;8(2):119-30 [16098465.001]
  • [Cites] Anticancer Res. 2005 May-Jun;25(3A):1699-702 [16033085.001]
  • [Cites] Pediatr Neurol. 2005 Apr;32(4):221-8 [15797177.001]
  • [Cites] Arch Dermatol. 2005 Jan;141(1):71-4 [15655144.001]
  • [Cites] Neuroradiology. 1997 Sep;39(9):639-41 [9335062.001]
  • [Cites] Am J Hum Genet. 1993 Aug;53(2):305-13 [8328449.001]
  • [Cites] Glia. 1992;6(1):1-8 [1355074.001]
  • [Cites] Cancer. 1986 Mar 15;57(6):1225-9 [3080222.001]
  • [Cites] Ophthalmology. 1984 Aug;91(8):929-35 [6436764.001]
  • [Cites] J Neurosci Res. 2004 Mar 15;75(6):817-24 [14994342.001]
  • [Cites] Neurology. 2003 Nov 25;61(10):1397-400 [14638962.001]
  • [Cites] Neurochem Int. 2003 Dec;43(7):621-8 [12892649.001]
  • [Cites] Neurology. 2002 Sep 10;59(5):759-61 [12221173.001]
  • [Cites] Am J Hum Genet. 2001 May;68(5):1110-8 [11283797.001]
  • [Cites] Brain Res. 2000 Dec 29;887(2):250-8 [11134613.001]
  • [Cites] Oncologist. 2000;5(6):477-85 [11110599.001]
  • [Cites] FEBS Lett. 2000 Dec 15;486(3):203-7 [11119704.001]
  • [Cites] Nat Genet. 2000 Sep;26(1):109-13 [10973261.001]
  • [Cites] Pediatrics. 2000 Mar;105(3 Pt 1):608-14 [10699117.001]
  • [Cites] J Comp Neurol. 2005 Dec 19;493(3):370-80 [16261532.001]
  • (PMID = 20029672.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2796235
  •  go-up   go-down


47. Xu Y, Jing Y, Ma S, Ma F, Wang Y, Ma W, Li Q: Primary angioleiomyoma in the sellar region: a case report and literature review. Clin Neuropathol; 2010 Jan-Feb;29(1):21-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Angioleiomyoma (vascular leiomyomas, angiomyoma) is a rare, benign soft tissue tumor which consists of a mixture of well-differentiated smooth muscle cells and thick-walled vessels.
  • Gross total resection of the tumor was then performed.
  • The pertinent literature regarding the features of this tumor was reviewed and discussed.
  • CONCLUSIONS: Intracranial angioleiomyoma is a benign soft tissue tumor with excellent prognosis.
  • Early diagnosis of this tumor is difficult.
  • [MeSH-major] Angiomyoma / pathology. Brain / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Adrenocorticotropic Hormone / metabolism. Early Diagnosis. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurologic Examination. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20040329.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone
  • [Number-of-references] 14
  •  go-up   go-down


48. Kalamarides M, Peyre M, Giovannini M: Meningioma mouse models. J Neurooncol; 2010 Sep;99(3):325-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas, although mostly benign, may sometimes present aggressive features and raise issues concerning alternative treatment options besides surgery.
  • As rodents very rarely develop spontaneous meningiomas, animal models have been first developed by implanting human meningioma cells derived from a primary tumor and meningioma cell lines subcutaneously into athymic mice.
  • Induction of de novo meningiomas in rodents with mutagens, such as nitrosourea, has also been reported.
  • Advances in our understanding of molecular genetics of meningioma have pinpointed the central role of NF2 tumor suppressor gene in the pathogenesis of those tumors.
  • [MeSH-major] Disease Models, Animal. Meningeal Neoplasms / pathology. Meningioma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] J Neurosurg. 2008 Feb;108(2):304-10 [18240927.001]
  • [Cites] Mod Pathol. 2001 Mar;14(3):197-201 [11266526.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):545-50 [2477514.001]
  • [Cites] Neurosurgery. 2007 Apr;60(4):750-9; discussion 759-60 [17415213.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Genes Dev. 2000 Jul 1;14(13):1617-30 [10887156.001]
  • [Cites] Proc Soc Exp Biol Med. 1977 May;155(1):85-8 [193127.001]
  • [Cites] Int J Mol Med. 2003 Dec;12(6):943-7 [14612971.001]
  • [Cites] Brain Pathol. 2008 Jan;18(1):62-70 [17924978.001]
  • [Cites] J Neurosurg. 1995 May;82(5):864-73 [7714613.001]
  • [Cites] Br J Cancer. 1978 Apr;37(4):644-7 [646935.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):130-5; discussion 135-6 [9442514.001]
  • [Cites] Neurosurgery. 2007 May;60(5):787-98; discussion 787-98 [17460514.001]
  • [Cites] J Neurosurg. 2007 Mar;106(3):455-62 [17367069.001]
  • [Cites] J Med Genet. 1992 Dec;29(12 ):841-6 [1479598.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Surg Neurol. 2001 May;55(5):275-83 [11516467.001]
  • [Cites] Genes Dev. 2002 May 1;16(9):1060-5 [12000789.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 2001 Aug;15(4):328-34 [11599449.001]
  • [Cites] Toxicol Pathol. 2007 Oct;35(6):780-7 [17943659.001]
  • [Cites] J Neurosci. 1997 Apr 1;17(7):2376-82 [9065498.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 1987 Apr;66(4):584-7 [3559725.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):326-32 [14672264.001]
  • [Cites] Clin Neuropathol. 1994 Mar-Apr;13(2):82-7 [8205731.001]
  • [Cites] Hum Pathol. 1997 Apr;28(4):416-20 [9104940.001]
  • [Cites] J Neurosurg. 2001 Mar;94(3):487-92 [11235955.001]
  • [Cites] Exp Toxicol Pathol. 2008 Aug;60(4-5):247-51 [18524558.001]
  • [Cites] Neurosurgery. 1990 Sep;27(3):389-95; discussion 396 [2234331.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Neoplasia. 2002 Jul-Aug;4(4):304-11 [12082546.001]
  • [Cites] J Neurosurg. 2000 Feb;92(2):306-14 [10659019.001]
  • [Cites] Nature. 1995 Dec 14;378(6558):720-4 [7501018.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Brain Tumor Pathol. 1997;14 (2):139-43 [15726793.001]
  • [Cites] Cell. 1987 Nov 6;51(3):503-12 [2822260.001]
  • [Cites] Neurology. 1997 Jul;49(1):267-70 [9222206.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6090-3 [7954452.001]
  • [Cites] Brain Pathol. 2005 Jan;15(1):55-65 [15779237.001]
  • [Cites] Genes Dev. 1998 Apr 15;12(8):1121-33 [9553042.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 May;79(5):574-80 [17766430.001]
  • [Cites] Surg Neurol. 2008 Sep;70(3):295-307; discussion 307 [18261772.001]
  • [Cites] Cell Prolif. 2005 Feb;38(1):3-12 [15679862.001]
  • [Cites] Toxicol Pathol. 2000 Jan-Feb;28(1):202-14 [10669008.001]
  • [Cites] Brain Pathol. 2008 Apr;18(2):172-9 [18093250.001]
  • [Cites] Lab Invest. 2005 Sep;85(9):1163-71 [15965488.001]
  • (PMID = 20734219.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


49. Feng Y, Yang ZG, Chen T, Wang Q, Deng W: Giant plexiform neurofibroma with hemorrhage in cranio-maxillofacial region as depicted on CT and MRI. Eur J Med Res; 2010 Feb 26;15(2):84-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plexiform neurofibroma (PN) is a rare benign tumor and a special subtype of neurofibromatosis type 1 (NF1).
  • [MeSH-major] Hemorrhage / diagnosis. Maxillary Neoplasms / diagnosis. Neurofibroma, Plexiform / diagnosis

  • Genetic Alliance. consumer health - Neurofibroma.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Med Genet. 2000 May 15;92(2):132-5 [10797438.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jan;176(1):75-82 [11133542.001]
  • [Cites] AJR Am J Roentgenol. 2001 Feb;176(2):493-5 [11159102.001]
  • [Cites] Radiographics. 2001 May-Jun;21(3):601-12 [11353109.001]
  • [Cites] Can J Gastroenterol. 2001 Dec;15(12):835-7 [11773950.001]
  • [Cites] Pediatrics. 2008 Mar;121(3):633-42 [18310216.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):79-82 [16029330.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Jan;27(1):126-8 [16418370.001]
  • [Cites] Brain Dev. 2006 Jun;28(5):275-80 [16481142.001]
  • [Cites] Head Neck. 2002 Feb;24(2):207-11 [11891951.001]
  • (PMID = 20452890.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC3352051
  •  go-up   go-down


50. Nohara H, Furuya K, Kawahara N, Iijima A, Yako K, Shibahara J, Kirino T: Lymphoplasmacyte-rich meningioma with atypical invasive nature. Neurol Med Chir (Tokyo); 2007 Jan;47(1):32-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was subtotally removed.
  • Histological examination showed the tumor had invaded the normal brain tissue despite its benign grade in the World Health Organization classification.
  • The Ki-67 staining index using MIB-1 monoclonal antibody was relatively high. (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography revealed high uptake in the tumor.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Plasma Cells
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245013.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. Somerset HL, Kleinschmidt-DeMasters BK, Rubinstein D, Breeze RE: Osteochondroma of the convexity: pathologic-neuroimaging correlates of a lesion that mimics high-grade meningioma. J Neurooncol; 2010 Jul;98(3):421-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial chondromas are uncommon benign lesions usually attached to dura and located over the convexity of the skull.
  • Osteochondromas are even rarer and additionally contain a benign bony component.
  • Extensive histological sectioning revealed a benign osteochondroma predominantly composed of lobules of hypocellular cartilage.
  • Microdissection of the different components revealed that the multifocal, spicule-like bright foci interpreted as hemorrhage on neuroimaging studies were instead foci of benign bone containing metaplastic bone marrow with trilineage hematopoietic cell populations and adipose tissue.
  • Rare convexity osteochondromas may be mistaken for high-grade meningiomas on neuroimaging studies; their avascular nature, coupled with their complex signal pattern can serve as clues to the correct pre-operative diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Dura Mater / pathology. Meningeal Neoplasms / physiopathology. Meningioma / physiopathology. Osteochondroma / pathology

  • Genetic Alliance. consumer health - Meningioma.
  • Genetic Alliance. consumer health - Osteochondroma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Neurosci. 2003 Jan;10(1):106-8 [12464537.001]
  • [Cites] Br J Neurosurg. 1998 Aug;12 (4):380-4 [10070437.001]
  • [Cites] Skull Base Surg. 1997;7(1):49-55 [17171008.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):331-4 [11213975.001]
  • [Cites] J Neurooncol. 2006 Oct;80(1):21-5 [16937014.001]
  • [Cites] J Clin Neurosci. 2008 Dec;15(12):1406-9 [18842412.001]
  • [Cites] AJNR Am J Neuroradiol. 1989 Sep-Oct;10(5 Suppl):S7-8 [2505578.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):610 [9488323.001]
  • [Cites] Neurosurgery. 1985 Mar;16(3):412-5 [3982625.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(1):53-6 [1811715.001]
  • [Cites] Clin Radiol. 1968 Jul;19(3):327-33 [5302924.001]
  • [Cites] Int J Oral Maxillofac Surg. 2007 Oct;36(10 ):959-62 [17629457.001]
  • [Cites] J Comput Assist Tomogr. 1981 Feb;5(1):109-15 [6972390.001]
  • [Cites] Neurochirurgie. 2007 Dec;53(6):491-4 [18061630.001]
  • [Cites] Neurocirugia (Astur). 2007 Jun;18(3):241-6 [17622464.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):419-20, 423 [12946032.001]
  • [Cites] Surg Neurol. 1993 Dec;40(6):495-8 [8235973.001]
  • [Cites] Br J Dermatol. 1977 Mar;96(3):317-22 [869989.001]
  • (PMID = 20012156.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Kyprianou I, Nassab R: A comparative study of referral patterns and management of patients with malignant brain tumours in Birmingham, UK, and Toronto, Canada. Br J Neurosurg; 2005 Jun;19(3):229-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparative study of referral patterns and management of patients with malignant brain tumours in Birmingham, UK, and Toronto, Canada.
  • The management of malignant brain tumours comprises a huge financial burden to any health care system.
  • The investigation consisted of a retrospective analysis of case records of patients identified as having malignant brain tumours who had been operated on at the two centres during the period 1997-1998.
  • Sixty-eight and 100 patients in Birmingham and Toronto, respectively, were identified from the registers following exclusion of patients with benign or low-grade tumours.
  • Both centres were found to be similar with respect to sociodemographic factors of patients with malignant brain tumours.
  • [MeSH-major] Brain Neoplasms / epidemiology. Referral and Consultation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16455523.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


53. Salomir R, Delemazure AS, Palussière J, Rouvière O, Cotton F, Chapelon JY: Image-based control of the magnetic resonance imaging-guided focused ultrasound thermotherapy. Top Magn Reson Imaging; 2006 Jun;17(3):139-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) a versatile, nonionizing physical agent for therapy and (2) a state-of-the art diagnosis and on-line monitoring tool.
  • A commercially available, Food and Drug Administration-approved device using the MRI-guided FUS exists since 2004 for the ablation of benign tumors (uterine fibroids); however, the ultimate goal of the technological, methodological, and medical research in this field is to provide a clinical-routine tool for fighting localized cancer.
  • This paper reviews some significant developments reported in the literature related to the image-based control of the FUS therapy for kidney, breast, prostate, and brain, including the own experience of the authors on the active feedback control of the temperature during FUS ablation.
  • [MeSH-major] Brain Neoplasms / therapy. Breast Neoplasms / therapy. Kidney Neoplasms / therapy. Magnetic Resonance Imaging / methods. Prostatic Neoplasms / therapy. Ultrasonic Therapy / methods


54. Benesch M, Windelberg M, Sauseng W, Witt V, Fleischhack G, Lackner H, Gadner H, Bode U, Urban C: Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors. Ann Oncol; 2008 Apr;19(4):807-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
  • PATIENTS AND METHODS: Fifteen patients (male: n = 8; female: n = 7; median age, 14.6 years) received bevacizumab for recurrent or progressive solid tumors (carcinoma: n = 3; neuroblastoma: n = 2; astrocytoma grade III: n = 2; rhabdomyosarcoma: n = 2; nephroblastoma: n = 2; benign vascular tumors: n = 2; synovial sarcoma: n = 1; and malignant hemangiopericytoma: n = 1) on a compassionate basis.
  • CONCLUSIONS: Bevacizumab seems to have a good acute safety profile and some antitumor activity in heavily pretreated children and young adults with recurrent solid tumors.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056650.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 2S9ZZM9Q9V / Bevacizumab
  •  go-up   go-down


55. Ruge JR, Liu J: Use of 5-aminolevulinic acid for visualization and resection of a benign pediatric brain tumor. J Neurosurg Pediatr; 2009 Nov;4(5):484-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of 5-aminolevulinic acid for visualization and resection of a benign pediatric brain tumor.
  • Intraoperatively, the residual tumor fluoresced, allowing for better visualization.
  • [MeSH-major] Aminolevulinic Acid. Astrocytoma / diagnosis. Astrocytoma / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Neurosurgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19877785.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


56. Dumortier J, Guillaud O, Walter T, Ber CE, Partensky C, Boillot O, Scoazec JY: Liver transplantation for multiple angiomyolipomas complicating tuberous sclerosis complex. Gastroenterol Clin Biol; 2010 Sep;34(8-9):494-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tuberous sclerosis complex is a genetic multisystem disorder characterised by widespread hamartomas in several organs, including the brain, heart, skin, eyes, kidney, lung, and liver.
  • Seventeen tumors, from 2 to 16 cm in diameter, were identified at examination of the liver explant.
  • In conclusion, this unusual indication of liver transplantation underlines the interest of this therapeutic approach for benign tumors for which the multiplicity of the lesions and their huge volume prevent any attempt at surgical resection.
  • [MeSH-major] Angiomyolipoma / surgery. Liver Neoplasms / surgery. Liver Transplantation. Neoplasms, Multiple Primary / surgery. Tuberous Sclerosis / complications


57. Marhold F, Preusser M, Dietrich W, Prayer D, Czech T: Clinicoradiological features of rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle: report of four cases and literature review. J Neurooncol; 2008 Dec;90(3):301-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicoradiological features of rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle: report of four cases and literature review.
  • BACKGROUND: Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a recently characterized rare tumor entity.
  • Despite benign histological features and a reported favorable postoperative course, there is still limited clinical experience with this tumor.
  • Mean age at diagnosis was 35 years, and the median follow-up was 19 (range 2-30) months.
  • RESULTS: Patient 1 presented on an emergency basis due to intratumoral hemorrhage and tumor enlargement followed by life-threatening obstructive hydrocephalus.
  • CONCLUSIONS: The spectrum of presenting symptoms of RGNT is wide, nonspecific, and typically depends on tumor size and extent.
  • This tumor entity should be considered in the differential diagnosis of posterior fossa masses in order to avoid undue surgical aggressiveness.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnostic imaging. Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / diagnostic imaging. Ganglioglioma / diagnostic imaging. Ganglioglioma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Res Pract. 2007;203(8):613-9 [17651910.001]
  • [Cites] J Radiol. 2006 Jun;87(6 Pt 2):748-63 [16778745.001]
  • [Cites] Surg Neurol. 2005 Apr;63(4):375-9 [15808729.001]
  • [Cites] Am J Surg Pathol. 2002 May;26(5):582-91 [11979088.001]
  • [Cites] Acta Neuropathol. 2006 Aug;112(2):231-3 [16816942.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):195-7 [15690138.001]
  • [Cites] Brain Pathol. 2007 Jul;17(3):308-13 [17598823.001]
  • [Cites] Acta Neuropathol. 1995;89(4):385-90 [7610772.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Apr;32(2):217-20 [16599951.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):228-33 [17284107.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):506-8 [12915951.001]
  • [Cites] J Neurosurg. 2006 Jul;105(1):129-31 [16871887.001]
  • (PMID = 18777116.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein
  • [Number-of-references] 14
  •  go-up   go-down


58. Scoles DR: The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta; 2008 Jan;1785(1):32-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis 2 (NF2) tumor suppressor protein merlin is commonly mutated in human benign brain tumors.
  • Review of all of the merlin interacting proteins and functional consequences of losses of these interactions reveals multiple merlin actions in PI3-kinase, MAP kinase and small GTPase signaling pathways that might be targeted to inhibit the proliferation of NF2 tumors.
  • [MeSH-minor] Animals. Binding Sites. Cytoskeletal Proteins / metabolism. Humans. Models, Biological. Protein Folding. Tumor Suppressor Proteins / administration & dosage. Tumor Suppressor Proteins / metabolism


59. Zekri JM, Manifold IH, Wadsley JC: Metastatic struma ovarii: late presentation, unusual features and multiple radioactive iodine treatments. Clin Oncol (R Coll Radiol); 2006 Dec;18(10):768-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic malignant struma ovarii is rare and there is a lack of agreement on the criteria of diagnosis and the lines of management.
  • Here we describe a patient with struma ovarii that was initially diagnosed as benign and presented 10 years later with distant metastases.
  • The case was associated with a number of unusual features and challenging management issues, such as a delayed diagnosis of recurrence, functioning metastases with treatment consequences, tumour lysis-induced thyrotoxicosis and cerebrospinal fluid rhinorrhea.
  • The diagnosis and management of struma ovarii should be led by an expert multidisciplinary team.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / radiotherapy. Struma Ovarii / diagnosis. Struma Ovarii / radiotherapy
  • [MeSH-minor] Adult. Brain Neoplasms / pathology. Brain Neoplasms / secondary. Diagnosis, Differential. Female. Humans. Iodine Radioisotopes / therapeutic use. Neoplasm Metastasis. Ovarian Follicle / pathology. Thyroglobulin / metabolism. Thyroid Neoplasms / diagnosis. Thyroid Neoplasms / secondary. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. THYROGLOBULIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168212.001).
  • [ISSN] 0936-6555
  • [Journal-full-title] Clinical oncology (Royal College of Radiologists (Great Britain))
  • [ISO-abbreviation] Clin Oncol (R Coll Radiol)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Iodine Radioisotopes; 9010-34-8 / Thyroglobulin
  •  go-up   go-down


60. Wang XY, Xu SJ, Li XG: Post-operative implantation metastasis of craniopharyngioma: a case report. J Int Med Res; 2010 Sep-Oct;38(5):1876-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Craniopharyngiomas are histologically benign epithelial tumours arising from squamous epithelial remnants of Rathke's pouch, which have a tendency to invade surrounding structures and recur after apparently complete resection.
  • They represent the most frequent non-glial tumour in children, accounting for approximately 5% of paediatric brain neoplasms.
  • [MeSH-major] Craniopharyngioma / secondary. Neoplasm Recurrence, Local / pathology. Pituitary Neoplasms / pathology

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21309505.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


61. Duggal N, Taylor R, Zou GY, Hammond RR: Dysembryoplastic neuroepithelial tumours: clinical, proliferative and apoptotic features. J Clin Pathol; 2008 Jan;61(1):127-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: Dysembryoplastic neuroepithelial tumours (DNTs) have been considered benign lesions characterised by a chronic, indolent clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17513508.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down


62. Smith MC, Ryken TC, Buatti JM: Radiotoxicity after conformal radiation therapy for benign intracranial tumors. Neurosurg Clin N Am; 2006 Apr;17(2):169-80, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotoxicity after conformal radiation therapy for benign intracranial tumors.
  • Acoustic schwannomas, skull base meningiomas, and pituitary adenomas are benign intracranial tumors frequently managed with radiotherapy.
  • Control rates after treatment for each of these tumors are generally high, and toxicity from treatment is relatively low.
  • Side effect profiles depend on the tumor location, the volume treated, the dose delivered, and the presence of nearby critical structures.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Neuroma, Acoustic / radiotherapy. Radiotherapy, Conformal / adverse effects

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793508.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


63. Huang H, Hara A, Homma T, Yonekawa Y, Ohgaki H: Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol; 2005 Oct;64(10):891-901
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma (WHO grade I) is a circumscribed, slowly growing, benign astrocytoma that most frequently develops in the cerebellar hemispheres and in midline structures and occurs predominantly in childhood and adolescence.
  • To search for potential molecular mechanisms underlying its benign biologic behavior, we compared gene expression profiles of pilocytic astrocytomas (8 cases) with those of normal cerebellum (4 cases), low-grade astrocytomas (WHO grade II; 15 cases), and oligodendrogliomas (WHO grade II; 17 cases) by cDNA array analysis.
  • These results suggest that gene expression profiles of pilocytic astrocytomas differ significantly from those of diffusely infiltrating low-grade gliomas and that their benign biologic behavior may be related to upregulation of immune defense-associated genes.
  • [MeSH-major] Astrocytoma / genetics. Astrocytoma / immunology. Brain Neoplasms / genetics. Brain Neoplasms / immunology. Gene Expression. Immunity / genetics


64. Gläsker S: Central nervous system manifestations in VHL: genetics, pathology and clinical phenotypic features. Fam Cancer; 2005;4(1):37-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The pathogenesis of these lesions remains unclear to date; however, biallelic inactivation of the VHL tumor suppressor gene is thought to be an important step.
  • These benign tumors occur frequently in patients with VHL disease and produce symptoms by mass effect either by the tumor itself or an accompanying cyst or edema.
  • Genetic testing for VHL germline mutations is recommended in all patients with hemangioblastoma and yearly screening, including MRI of the brain and spine, is recommended for all VHL disease patients.
  • Treatment of these tumors is mainly surgical.
  • In general, surgery is indicated in symptomatic hemangioblastomas and eventually also in asymptomatic tumors that exhibit radiographic progression.
  • The tumors can usually be completely removed by dissection in the plane between tumor and CNS tissue and coagulating and cutting of the numerous feeding vessels with low power.
  • Local tumor recurrences are rare.
  • [MeSH-major] Central Nervous System Neoplasms / etiology. Central Nervous System Neoplasms / genetics. Hemangioblastoma / etiology. Hemangioblastoma / genetics. von Hippel-Lindau Disease / complications. von Hippel-Lindau Disease / genetics

  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 [5279523.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):82-94 [12546356.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:179-86 [9782249.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):898-901 [1431953.001]
  • [Cites] Hum Mol Genet. 1992 May;1(2):131-3 [1301149.001]
  • [Cites] Neurosurgery. 2002 May;50(5):1059-63 [11950409.001]
  • [Cites] Neurosurgery. 1983 Mar;12(3):327-30 [6682491.001]
  • [Cites] J Med Genet. 1996 Feb;33(2):120-7 [8929948.001]
  • [Cites] J Neurosurg. 1989 Jan;70(1):24-30 [2909683.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17 (3):525-31 [8881249.001]
  • [Cites] Q J Med. 1990 Nov;77(283):1151-63 [2274658.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):591-6 [8814161.001]
  • [Cites] AJR Am J Roentgenol. 2000 Feb;174(2):377-82 [10658709.001]
  • [Cites] Zentralbl Neurochir. 1997;58(1):1-6 [9235816.001]
  • [Cites] Medicine (Baltimore). 1997 Nov;76(6):381-91 [9413424.001]
  • [Cites] AJNR Am J Neuroradiol. 1992 Sep-Oct;13(5):1343-52 [1414827.001]
  • [Cites] Neuroradiology. 1997 Feb;39(2):86-9 [9045967.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758-62 [10567493.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] JAMA. 1997 May 14;277(18):1461-6 [9145719.001]
  • [Cites] Br J Neurosurg. 1999 Oct;13(5):504-7 [10627785.001]
  • [Cites] Neurosurgery. 1989 Nov;25(5):695-8 [2586723.001]
  • [Cites] Histopathology. 1998 Jul;33(1):2-10 [9726042.001]
  • [Cites] J Neurosurg. 1978 Jul;49(1):143-5 [566308.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):641-4; discussion 644-5 [10949438.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2001 May;70(5):644-8 [11309459.001]
  • [Cites] J Neurosurg. 2002 Jul;97(1 Suppl):1-6 [12120629.001]
  • [Cites] Medicine (Baltimore). 1989 Jan;68(1):1-29 [2642584.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):106-16 [12546358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Jun 1;35(3):493-9 [8655372.001]
  • [Cites] Arch Neurol. 1976 Jun;33(6):435-41 [945725.001]
  • [Cites] Neurosurg Rev. 1996;19(3):147-51 [8875501.001]
  • [Cites] Hum Pathol. 1997 May;28(5):540-3 [9158701.001]
  • [Cites] Neurosurgery. 1988 Mar;22(3):518-22 [3129668.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):95-105 [12546357.001]
  • [Cites] Adv Tech Stand Neurosurg. 1993;20:197-304 [8397535.001]
  • [Cites] J Neurosurg. 1994 Dec;81(6):937-40 [7965128.001]
  • [Cites] Neurochirurgia (Stuttg). 1990 Jul;33(4):100-5 [2395499.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):502-5; discussion 505 [8413884.001]
  • [Cites] Vasa. 1987;16(4):309-11 [3424948.001]
  • [Cites] Neurol Med Chir (Tokyo). 1985 Apr;25(4):268-74 [2412149.001]
  • [Cites] Neurosurgery. 2003 Dec;53(6):1306-13; discussion 1313-4 [14633297.001]
  • [Cites] Neurology. 1991 Jan;41(1):41-6 [1985294.001]
  • (PMID = 15883708.001).
  • [ISSN] 1389-9600
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 45
  •  go-up   go-down


65. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH: Central nervous system tumors. Mayo Clin Proc; 2007 Oct;82(10):1271-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system tumors.
  • Central nervous system tumors are relatively common in the United States, with more than 40,000 cases annually.
  • Although more than half of these tumors are benign, they can cause substantial morbidity.
  • Malignant primary brain tumors are the leading cause of death from solid tumors in children and the third leading cause of death from cancer in adolescents and adults aged 15 to 34 years.
  • Whereas magnetic resonance imaging helps define the anatomic extent of tumor, biopsy is often required to confirm the diagnosis.
  • Treatment depends on the histologic diagnosis.
  • Benign tumors are usually curable with surgical resection or radiation therapy including stereotactic radiation; however, most patients with malignant brain tumors benefit from chemotherapy either at the time of initial diagnosis or at tumor recurrence.
  • Metastases to the brain remain a frequent and morbid complication of solid tumors but are frequently controlled with surgery or radiation therapy.
  • Unfortunately, the mortality rate from malignant brain tumors remains high, despite initial disease control.
  • This article provides an overview of current diagnostic and treatment approaches for patients with primary and metastatic brain tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Glioma / diagnosis. Glioma / therapy. Humans

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908533.001).
  • [ISSN] 0025-6196
  • [Journal-full-title] Mayo Clinic proceedings
  • [ISO-abbreviation] Mayo Clin. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 52
  •  go-up   go-down


66. Jett K, Friedman JM: Clinical and genetic aspects of neurofibromatosis 1. Genet Med; 2010 Jan;12(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Neurofibromatosis 1 is an autosomal dominant disorder characterized by multiple café-au-lait spots, axillary and inguinal freckling, multiple cutaneous neurofibromas, and iris Lisch nodules.
  • Less common but potentially more serious manifestations include plexiform neurofibromas, optic nerve and other central nervous system gliomas, malignant peripheral nerve sheath tumors, scoliosis, tibial dysplasia, and vasculopathy.
  • The diagnosis of neurofibromatosis 1 is usually based on clinical findings.
  • Almost one half of all affected individuals have de novo mutations.
  • Molecular genetic testing is available clinically but is infrequently needed for diagnosis.
  • Surgery to remove both benign and malignant tumors or to correct skeletal manifestations is sometimes warranted.
  • Annual physical examination by a physician familiar with the disorder is recommended.
  • Other recommendations include ophthalmologic examinations annually in children and less frequently in adults, regular developmental assessment in children, regular blood pressure monitoring, and magnetic resonance imaging for follow-up of clinically suspected intracranial and other internal tumors.
  • [MeSH-minor] Adolescent. Bone and Bones / pathology. Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Brain Neoplasms / pathology. Brain Neoplasms / physiopathology. Child. Child, Preschool. Eye Diseases / etiology. Genes, Neurofibromatosis 1. Headache / etiology. Humans. Intelligence. Learning Disorders / etiology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20027112.001).
  • [ISSN] 1530-0366
  • [Journal-full-title] Genetics in medicine : official journal of the American College of Medical Genetics
  • [ISO-abbreviation] Genet. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 222
  •  go-up   go-down


67. Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME: Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. J Med Genet; 2006 Apr;43(4):289-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes.
  • In recent years the use of radiation treatment for benign tumours has increased with the advent of stereotactic delivery and, in particular, single high dose gamma knife therapy.
  • This has been particularly true for benign CNS (central nervous system) tumours such as vestibular schwannoma, meningioma, pituitary adenoma, and haemangioblastoma.
  • While short term follow up in patients with isolated tumours suggests this treatment is safe, there are particular concerns regarding its use in childhood and in tumour predisposing syndromes.
  • We have reviewed the use of radiation treatment in these contexts with particular regard to malignant transformation and new tumour induction.
  • This review indicates that much more caution is warranted regarding the use of radiation treatment for benign tumours in childhood and in tumour prone conditions such as the neurofibromatoses.
  • [MeSH-major] Cell Transformation, Neoplastic. Neoplasms / radiotherapy. Neoplasms, Radiation-Induced / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1986 May 15;57(10):2006-21 [3082508.001]
  • [Cites] Br J Cancer. 1986 May;53(5):661-71 [3718823.001]
  • [Cites] N Engl J Med. 1987 May 21;316(21):1289-94 [3574400.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Br J Neurosurg. 1991;5(6):643-6 [1772613.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] J Clin Oncol. 1993 Feb;11(2):262-70 [8426203.001]
  • [Cites] Radiology. 1993 Jun;187(3):843-6 [8497642.001]
  • [Cites] Arch Intern Med. 1996 Sep 9;156(16):1873-8 [8790083.001]
  • [Cites] Int J Radiat Biol. 1996 Aug;70(2):145-50 [8794843.001]
  • [Cites] J Med Genet. 1996 Feb;33(2):120-7 [8929948.001]
  • [Cites] Br J Cancer. 1998 Jun;77(12):2181-92 [9649131.001]
  • [Cites] Neurosurgery. 1998 Jul;43(1):28-34; discussion 34-5 [9657185.001]
  • [Cites] Minim Invasive Neurosurg. 2003 Aug;46(4):254-6 [14506573.001]
  • [Cites] Int J Cancer. 2003 Dec 10;107(5):791-6 [14566829.001]
  • [Cites] J Med Genet. 2003 Nov;40(11):802-6 [14627667.001]
  • [Cites] Can J Neurol Sci. 2003 Nov;30(4):378-83 [14672272.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):109-10 [14693854.001]
  • [Cites] Ophthalmology. 2004 Jan;111(1):150-3 [14711727.001]
  • [Cites] Lancet. 2004 Jan 31;363(9406):345-51 [15070562.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:65-73 [9782237.001]
  • [Cites] Stereotact Funct Neurosurg. 1998 Oct;70 Suppl 1:179-86 [9782249.001]
  • [Cites] Ann Neurol. 1999 Mar;45(3):393-6 [10072056.001]
  • [Cites] J Med Genet. 1999 Mar;36(3):197-203 [10204844.001]
  • [Cites] Br J Cancer. 1999 Apr;79(11-12):1884-93 [10206309.001]
  • [Cites] J Neurosurg. 1999 May;90(5):815-22 [10223445.001]
  • [Cites] Arch Dis Child. 1999 Jan;80(1):1-3 [10325750.001]
  • [Cites] Am J Hum Genet. 1999 Sep;65(3):784-94 [10441587.001]
  • [Cites] Cancer. 1963 Aug;16:1003-14 [14050004.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:195-9 [15662809.001]
  • [Cites] Br J Neurosurg. 2004 Aug;18(4):338-42 [15702831.001]
  • [Cites] Br J Neurosurg. 2005 Feb;19(1):5-12 [16147576.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2570-5 [16735710.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Pediatr. 1989 May;114(5):788-92 [2497236.001]
  • [Cites] Surgery. 1991 Oct;110(4):691-5 [1833847.001]
  • [Cites] Br J Cancer. 1991 Nov;64(5):959-61 [1931625.001]
  • [Cites] Br J Cancer. 2000 Feb;82(4):998 [10732777.001]
  • [Cites] Otolaryngol Head Neck Surg. 2000 May;122(5):667-72 [10793343.001]
  • [Cites] Am J Otol. 2000 May;21(3):364-70 [10821550.001]
  • [Cites] Surg Neurol. 2000 Apr;53(4):383-89; discussion 389-90 [10825525.001]
  • [Cites] Br J Neurosurg. 2000 Apr;14(2):93-5 [10889878.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(6):641-4; discussion 644-5 [10949438.001]
  • [Cites] Cancer Invest. 1999;17(1):56-72 [10999050.001]
  • [Cites] Am J Hum Genet. 1999 Oct;65(4):995-1006 [10486318.001]
  • [Cites] Int J Cancer. 2000 Nov 15;88(4):672-8 [11058888.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Dec 1;48(5):1381-7 [11121637.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2000;12(5):300-4 [11315715.001]
  • [Cites] Int J Cancer. 2001 Aug 20;96(4):238-42 [11474498.001]
  • [Cites] Oncogene. 2001 Aug 2;20(34):4621-8 [11498785.001]
  • [Cites] J Neurosurg. 2001 Sep;95(3):518-21 [11565878.001]
  • [Cites] Radiat Res. 2002 Feb;157(2):158-65 [11835679.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6 [11894972.001]
  • [Cites] J Med Genet. 2002 May;39(5):311-4 [12011145.001]
  • [Cites] J Med Genet. 2002 May;39(5):315-22 [12011146.001]
  • [Cites] Arch Dis Child. 2002 Jul;87(1):65-70 [12089128.001]
  • [Cites] Lancet. 2002 Jul 27;360(9329):309-10 [12147377.001]
  • [Cites] Br J Neurosurg. 2002 Jun;16(3):284-9 [12201399.001]
  • [Cites] Brain. 2003 Jan;126(Pt 1):152-60 [12477702.001]
  • [Cites] Cancer. 2003 Feb 15;97(4):1084-92 [12569610.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):808-17 [12651207.001]
  • [Cites] Lancet. 2003 Mar 29;361(9363):1101-2 [12672316.001]
  • [Cites] Health Phys. 2003 Jul;85(1):47-59 [12852471.001]
  • [Cites] Cancer. 2003 Aug 1;98(3):618-24 [12879481.001]
  • [Cites] Tumori. 2003 Jul-Aug;89(4 Suppl):197-9 [12903592.001]
  • [Cites] Mayo Clin Proc. 2003 Jun;78(6):708-15 [12934780.001]
  • [Cites] Oncogene. 2003 Sep 1;22(37):5774-83 [12947385.001]
  • [Cites] Cancer. 2004 May 15;100(10):2246-52 [15139071.001]
  • [Cites] Neurochirurgie. 2004 Jun;50(2-3 Pt 2):367-76 [15179291.001]
  • [Cites] JAMA. 1967 Jan 23;199(4):280-1 [4224873.001]
  • [Cites] Am J Surg. 1968 Oct;116(4):518-23 [4300240.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] Ann Intern Med. 1977 Aug;87(2):160-4 [889197.001]
  • [Cites] J Natl Cancer Inst. 1979 Jun;62(6):1347-59 [286106.001]
  • [Cites] Arch Dermatol. 1980 Oct;116(10):1159-63 [7425663.001]
  • [Cites] Arch Pathol Lab Med. 1983 Jun;107(6):293-7 [6687792.001]
  • (PMID = 16155191.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 80
  • [Other-IDs] NLM/ PMC2563223
  •  go-up   go-down


68. Larouche V, Huang A, Bartels U, Bouffet E: Tumors of the central nervous system in the first year of life. Pediatr Blood Cancer; 2007 Dec;49(7 Suppl):1074-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumors of the central nervous system in the first year of life.
  • Among 1,289 infants identified from this literature review, the most common histological diagnoses are astrocytoma (30.5%), medulloblastoma (12.2%), ependymoma (11.1%), and choroid plexus tumors (11%).
  • Most tumors are supratentorial (65%).
  • The most important prognostic factors are histology (malignant vs. benign) and extent of resection.
  • Significant differences are noted for some tumor types by comparison with older children, for example in the aggressive behavior of low grade gliomas and the chemosensitivity of some high grade gliomas.
  • [MeSH-major] Brain Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17943961.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 71
  •  go-up   go-down


69. Rosenfeld A, Listernick R, Charrow J, Goldman S: Neurofibromatosis type 1 and high-grade tumors of the central nervous system. Childs Nerv Syst; 2010 May;26(5):663-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurofibromatosis type 1 and high-grade tumors of the central nervous system.
  • PURPOSE: Neurofibromatosis type 1 (NF1), a common genetic disorder, predisposes patients to the development of both benign and malignant tumors.
  • Although the most common central nervous system (CNS) tumor is a low-grade pilocytic astrocytoma of the optic pathway, there have been sporadic reports of NF1 patients with more aggressive CNS lesions.
  • METHODS: We conducted a retrospective review of all patients with NF1 and any CNS tumor being followed in the Children's Memorial Hospital NF1 Clinic.
  • RESULTS: Seven hundred forty patients with a diagnosis of NF1 were identified.
  • Of these, 145 (20%) patients had CNS tumors, 99 (68%) of whom had optic pathway tumors (OPTs).
  • Five patients (3%) were identified as having high-grade tumors, which consisted of anaplastic medulloblastoma (n = 1) and high-grade glioma (n = 4).
  • The mean age at diagnosis of NF1 was 2 years.
  • Currently, two patients are alive and receiving therapy at a mean of 10 months following diagnosis.
  • CONCLUSION: High-grade CNS tumors may occur in children with NF1.
  • Although tumors in NF patients are generally benign, clinicians should have a high index of suspicion of malignancy in patients whose tumors are in an unusual location or behave in an uncharacteristically aggressive manner.
  • [MeSH-major] Brain Neoplasms / complications. Neurofibromatosis 1 / complications


70. Ozen O, Demirhan B, Altinörs N: Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas. Clin Neuropathol; 2005 Sep-Oct;24(5):219-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Meningiomas for the most part are slow-growing benign tumors, but complete removal can be difficult and recurrence is an issue.
  • The aim of this study was to re-evaluate tumors diagnosed as meningioma previously in our hospital, according to the latest World Health Organization classification.
  • We also examined the relationships among parameters such as brain invasion, histological grade and Ki-67 and p53 expression in these tumors.
  • MATERIALS AND METHODS: Meningioma biopsy specimens numbering 60 (48 grade I, 11 grade II, and 1 grade III tumors) were examined immunohistochemically using monoclonal antibodies for Ki-67 (MIB-1) and p53 protein.
  • The MIB-1 labeling index (LI) for each tumor was calculated as a percentage based on the number of stained cells per total cells counted.
  • RESULTS: Of the 60 meningiomas, 7 (11.7%) exhibited brain invasion.
  • The mean MIB-1 LI values for the grade I and grade II tumors were 1.1% and 2.3%, respectively.
  • Brain invasion was not correlated with histological grade, MIB-1 LI, or p53 expression.
  • The number of cases was limited, but the findings also suggest that brain invasion is a prognostic parameter independent of grade, MIB-1 LI and p53 expression.
  • [MeSH-major] Biomarkers, Tumor / analysis. Ki-67 Antigen / biosynthesis. Meningeal Neoplasms / pathology. Meningioma / pathology. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167545.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


71. Knisely JP, Linskey ME: Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors. Neurosurg Clin N Am; 2006 Apr;17(2):149-67, vii
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Less common indications for stereotactic radiosurgery or fractionated radiotherapy for patients with benign brain tumors.
  • Microsurgical resection remains the mainstay of treatment for truly benign brain tumors that can be safely resected because of the potential for permanent cure with most histologic findings, including most of the histologic findings discussed in this article.
  • Physicians must keep in mind the indolent nature of many of the benign brain tumors and realize that many patients are likely to live out normal life spans if tumor control is achieved.
  • Therefore, it is not sufficient simply to consider local tumor control rates and short-term toxicity risks when choosing between surgery, stereotactic radiosurgery, and fractionated radiotherapy.
  • For benign brain tumors, these decisions may have consequences that last for decades.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Patient Selection
  • [MeSH-minor] Astrocytoma / diagnosis. Astrocytoma / radiotherapy. Astrocytoma / surgery. Chordoma / diagnosis. Chordoma / radiotherapy. Chordoma / surgery. Dose Fractionation. Glomus Tumor / diagnosis. Glomus Tumor / radiotherapy. Glomus Tumor / surgery. Humans. Magnetic Resonance Imaging. Neurocytoma / diagnosis. Neurocytoma / radiotherapy. Neurocytoma / surgery. Paraganglioma / diagnosis. Paraganglioma / radiotherapy. Paraganglioma / surgery. Paraganglioma, Extra-Adrenal / diagnosis. Paraganglioma, Extra-Adrenal / radiotherapy. Paraganglioma, Extra-Adrenal / surgery. Pinealoma / diagnosis. Pinealoma / radiotherapy. Pinealoma / surgery. Radiosurgery / methods. Skull Base Neoplasms / diagnosis. Skull Base Neoplasms / radiotherapy. Skull Base Neoplasms / surgery. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793507.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 148
  •  go-up   go-down


72. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC: 18F-FDOPA kinetics in brain tumors. J Nucl Med; 2007 Oct;48(10):1651-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDOPA kinetics in brain tumors.
  • Evaluation of tumor recurrence in neurooncology is another application.
  • Here, the kinetics of (18)F-FDOPA in brain tumors were investigated.
  • METHODS: A total of 37 patients underwent 45 studies; 10 had grade IV, 10 had grade III, and 13 had grade II brain tumors; 2 had metastases; and 2 had benign lesions.
  • Images representing venous structures, the striatum, and tumors were generated with factor analysis, and from these, input and output functions were derived with simple threshold techniques.
  • RESULTS: A 2-compartment model was able to describe (18)F-FDOPA kinetics in tumors and the cerebellum but not the striatum.
  • A 3-compartment model with corrections for tissue blood volume, metabolites, and partial volume appeared to be superior for describing (18)F-FDOPA kinetics in tumors and the striatum.
  • A significant correlation was found between influx rate constant K and late uptake (standardized uptake value from 65 to 75 min), whereas the correlation of K with early uptake was weak.
  • High-grade tumors had significantly higher transport rate constant k(1), equilibrium distribution volumes, and influx rate constant K than did low-grade tumors (P < 0.01).
  • Tumor uptake showed a maximum at about 15 min, whereas the striatum typically showed a plateau-shaped curve.
  • Logan graphical analysis yielded reliable estimates of the distribution volume and could separate newly diagnosed high-grade tumors from low-grade tumors.
  • CONCLUSION: A 2-compartment model was able to describe (18)F-FDOPA kinetics in tumors in a first approximation.
  • A 3-compartment model with corrections for metabolites and partial volume could adequately describe (18)F-FDOPA kinetics in tumors, the striatum, and the cerebellum.
  • This model suggests that (18)F-FDOPA was transported but not trapped in tumors, unlike in the striatum.
  • The shape of the uptake curve appeared to be related to tumor grade.
  • After an early maximum, high-grade tumors had a steep descending branch, whereas low-grade tumors had a slowly declining curve, like that for the cerebellum but on a higher scale.
  • [MeSH-major] Brain / metabolism. Brain / radionuclide imaging. Brain Neoplasms / metabolism. Brain Neoplasms / radionuclide imaging. Dihydroxyphenylalanine / analogs & derivatives. Image Interpretation, Computer-Assisted / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17873130.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 2C598205QX / fluorodopa F 18; 63-84-3 / Dihydroxyphenylalanine
  •  go-up   go-down


73. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


74. De Marinis L, Fusco A, Bianchi A, Aimaretti G, Ambrosio MR, Scaroni C, Cannavo S, Di Somma C, Mantero F, degli Uberti EC, Giordano G, Ghigo E: Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest; 2006 Jun;29(6):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.
  • It may occur after neurosurgical treatment of brain tumors arising near sella turcica.
  • The aim of this study was to evaluate pituitary function in particular GH deficiency (GHD) in patients submitted to neurosurgery for benign tumors of the central nervous system (CNS) not involving hypothalamic-pituitary region.
  • We observed 37 patients with benign brain tumors [13 males, 24 females, age: 54.6+/-13.9 yr; body mass index (BMI): 25.1+/-4.0 kg/m2] performing a basic evaluation of the pituitary function and a dynamic test of the GH/IGF-I axis [GHRH (1 microg/kg iv)+arginine (0.5 g/kg iv) test] for 3 and 12 months after the neurosurgical treatment.
  • This data suggests that hypopituitarism of various degree may develop in patients who are submitted to neurosurgery for primary brain tumors, even far from hypothalamic-pituitary region.
  • [MeSH-major] Brain Neoplasms / surgery. Hypopituitarism / etiology. Postoperative Complications

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] Endocrine. 2001 Jun;15(1):29-38 [11572322.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6355-60 [16144946.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):320-6 [15355447.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1615-8 [9589665.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1048-54 [15754737.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:26-33 [15761229.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Aug;18(8):833-9 [9701344.001]
  • [Cites] Horm Res. 2003;59 Suppl 1:1-11 [12566714.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Aug;23(4):307-14 [9292869.001]
  • [Cites] Expert Opin Pharmacother. 2004 May;5(5):1023-31 [15155105.001]
  • [Cites] Neurologist. 2004 May;10(3):113-30 [15140272.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):662-9 [10603007.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] Neurosurg Clin N Am. 2003 Oct;14(4):571-91 [15024802.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S114-7 [15135791.001]
  • [Cites] Eur J Pediatr. 1997 Oct;156(10):764-9 [9365064.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):663-9 [12447103.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] J Neurosci. 2000 Nov 1;20(21):7994-8004 [11050120.001]
  • [Cites] J Invest Surg. 2004 Sep-Oct;17(5):283-9 [15385261.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):477-85 [11836272.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • (PMID = 16840829.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Somatomedins; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; 94ZLA3W45F / Arginine; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


75. Yilmazlar S, Kocaeli H, Aksoy K: Quadrigeminal cistern lipoma. J Clin Neurosci; 2005 Jun;12(5):596-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intracranial lipomas are rare benign congenital neoplasms accounting for 0.1 to 0.5% of all primary brain tumours.
  • Approximately 50% are associated with other cerebral developmental disorders.
  • These slow growing benign lesions are usually asymptomatic and rarely require surgery.
  • [MeSH-major] Brain / pathology. Brain Neoplasms / diagnosis. Lipoma / diagnosis. Subarachnoid Space / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15936197.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


76. De Cerchio L, Contratti F, Fraioli MF: Dorsal dumb-bell melanotic schwannoma operated on by posterior and anterior approach: case report and a review of the literature. Eur Spine J; 2006 Oct;15 Suppl 5:664-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The schwannomas are benign tumors originating from Schwann cells which constitute the nerve sheath.
  • Histopathological examination revealed the diagnosis of melanotic schwannoma.
  • As the total removal of the melanotic neurinomas is mandatory to prevent possible malignant transformation of the tumor recurrence or regrowth, we believe that the posterior and trans-thoracic approach are the most suitable one for the dorsal dumb-bell schwannoma.
  • [MeSH-major] Neurilemmoma / diagnosis. Neurilemmoma / surgery. Neurosurgical Procedures / methods. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 1988 Sep;16(10):1199-205 [3060751.001]
  • [Cites] Neurochirurgie. 1988;34(3):210-7 [3054600.001]
  • [Cites] Eur J Radiol. 1990 Sep-Oct;11(2):138-42 [2253635.001]
  • [Cites] Am J Clin Pathol. 1991 Apr;95(4):484-9 [2014773.001]
  • [Cites] Ann Pathol. 1993;13(3):184-7 [8397544.001]
  • [Cites] Arch Anat Cytol Pathol. 1994;42(1):46-53 [8074546.001]
  • [Cites] Tumori. 1995 May-Jun;81(3):208-12 [7571031.001]
  • [Cites] Pathol Res Pract. 1996 Nov;192(11):1142-6; discussion 1147 [9122034.001]
  • [Cites] Cesk Patol. 1997 Nov;33(4):141-5 [9501653.001]
  • [Cites] Semin Diagn Pathol. 1998 Aug;15(3):216-24 [9711672.001]
  • [Cites] Diagn Cytopathol. 1998 Oct;19(4):298-302 [9784997.001]
  • [Cites] J Neurosurg Sci. 1998 Dec;42(4):245-9 [10404754.001]
  • [Cites] Am J Med Genet. 1999 Sep 3;86(1):62-5 [10440831.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):453-4, 458-9 [15605993.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):72-8 [15483077.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):151-6 [15690131.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2005 Mar;262(3):182-5 [15133690.001]
  • [Cites] Lancet Oncol. 2005 Jul;6(7):501-8 [15992699.001]
  • [Cites] Chin Med J (Engl). 2005 Sep 5;118(17):1451-61 [16157048.001]
  • [Cites] Arch Anat Cytol Pathol. 1995;43(3):160-3 [7574916.001]
  • [Cites] Histopathology. 1999 Dec;35(6):558-66 [10583580.001]
  • [Cites] J Neurol. 1999 Nov;246(11):1100-2 [10631648.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):413-8 [10701527.001]
  • [Cites] J Neurosurg. 2000 Apr;92(2 Suppl):241-5 [10763702.001]
  • [Cites] Neuroradiology. 2000 Apr;42(4):275-9 [10872172.001]
  • [Cites] Neuroradiology. 2000 Jun;42(6):458-61 [10929310.001]
  • [Cites] Rozhl Chir. 2001 Nov;80(11):572-4 [11794055.001]
  • [Cites] Neurochirurgie. 2003 Mar;49(1):31-8 [12736578.001]
  • [Cites] Histol Histopathol. 2003 Jul;18(3):925-34 [12792904.001]
  • [Cites] J Neurooncol. 2004 Jul;68(3):249-54 [15332329.001]
  • [Cites] Wien Klin Wochenschr. 2004;116 Suppl 2:93-6 [15506323.001]
  • [Cites] J Neurosurg. 1974 Aug;41(2):187-92 [4841875.001]
  • [Cites] Surg Neurol. 1975 Feb;3(2):79-81 [1118806.001]
  • [Cites] Neurosurgery. 1978 Jan-Feb;2(1):47-51 [683481.001]
  • [Cites] Thorax. 1979 Apr;34(2):243-6 [483192.001]
  • [Cites] Am J Surg Pathol. 1979 Feb;3(1):3-10 [534381.001]
  • [Cites] Cancer. 1980 Jul 15;46(2):391-7 [7388777.001]
  • [Cites] Cancer. 1980 Aug 15;46(4):718-24 [7397634.001]
  • [Cites] Neurosurgery. 1982 Jul;11(1 Pt 1):57-60 [7110568.001]
  • [Cites] Appl Pathol. 1984;2(2):110-5 [6537255.001]
  • [Cites] Ultrastruct Pathol. 1985;9(1-2):123-9 [4089993.001]
  • [Cites] Arch Anat Cytol Pathol. 1987;35(2):76-81 [3632063.001]
  • [Cites] Cancer. 1988 Jul 1;62(1):174-83 [3289725.001]
  • [Cites] Am J Surg Pathol. 1990 Mar;14(3):206-22 [2305928.001]
  • (PMID = 16947016.001).
  • [ISSN] 1432-0932
  • [Journal-full-title] European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  • [ISO-abbreviation] Eur Spine J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 45
  • [Other-IDs] NLM/ PMC1602204
  •  go-up   go-down


77. Rogers L, Gilbert M, Vogelbaum MA: Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol; 2010 Sep;99(3):393-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical (WHO grade II) meningiomas occupy an intermediate risk group between benign (WHO grade I) and anaplastic (WHO grade III) meningiomas.
  • We will discuss the definition, diagnosis, and treatment of patients with atypical meningioma; review the current phase II cooperative trials; and draw attention to some questions timely for pre-clinical and clinical research.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Clin Nucl Med. 2005 Nov;30(11):717-20 [16237292.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):41-7 [17361335.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Acta Neurochir (Wien). 1995;135(3-4):171-8 [8748810.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):386-408 [12946028.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1147-52 [18356472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Clin Radiol. 2007 Feb;62(2):109-19 [17207692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neuroradiology. 1990;32(6):467-73 [2287373.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Clin Nucl Med. 2009 Jan;34(1):7-10 [19092373.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):589-93 [12948465.001]
  • [Cites] Neuroradiology. 2006 Aug;48(8):513-20 [16786348.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Osaka City Med J. 1997 Dec;43(2):209-23 [9540343.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Oct;29(9):1630-5 [18583409.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 5;121(23):2415-9 [19102960.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:283-6 [15662826.001]
  • [Cites] Clin Imaging. 2008 Jan-Feb;32(1):22-7 [18164390.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:6-16 [6953802.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10 ):1574-82 [19377904.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174(12):624-8 [9879349.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):171-3 [14751635.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):70-4 [15685038.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 2010 Apr;66(4):661-8; discussion 668-9 [20305491.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A19-27; discussion A27-8 [18580776.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] J Neurooncol. 1998 Aug;39(1):65-70 [9760071.001]
  • [Cites] Curr Opin Neurol. 2010 Dec;23(6):563-70 [20885321.001]
  • [Cites] Radiologia. 2009 Jul-Aug;51(4):411-9 [19552929.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):946-50 [8847588.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):26-30 [8998144.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):65-72 [11158890.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Radiology. 2005 Jun;235(3):985-91 [15833979.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] J Neuroradiol. 1992;19(1):49-62 [1564530.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406 [19203844.001]
  • (PMID = 20740303.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


78. Kondziolka D, Flickinger JC, Lunsford LD: The principles of skull base radiosurgery. Neurosurg Focus; 2008;24(5):E11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stereotactic radiosurgery is commonly used for selected patients with benign cranial base tumors.
  • The goal of radiosurgery is cessation of tumor growth and preservation of neurological function.
  • [MeSH-major] Cranial Irradiation / methods. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Brain Stem / physiopathology. Brain Stem / surgery. Cerebellar Neoplasms / surgery. Cerebellopontine Angle / surgery. Cranial Nerve Injuries / prevention & control. Decompression, Surgical. Diagnostic Imaging. Humans. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Patient Selection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447740.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 16
  •  go-up   go-down


79. Lujan-Castilla PJ, Durán-Cruz M, Enríquez-Barrera M, García-Muñóz L, Hernández-Oviedo JO, Barragán-Pérez JA: [Stereotactic radiosurgery with linear accelerator (LINAC). Report of the technical experience in 100 cases treated at the Mexico General Hospital]. Gac Med Mex; 2005 Sep-Oct;141(5):367-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Radiocirugía estereotáxica con acelerador lineal (LINAC). Informe de la experiencia técnica en el manejo de 100 casos en el Hospital General de México.
  • METHODS: One hundred patients received treatment with LINAC stereotactic radiosurgery, 34 AVM, 22 meningiomas, 18 astrocytomas, 11 pituitary adenomas, 5 cavernous malformations, 3 acoustic neuromas, 3 craniopharyngiomas, 2 cases of epilepsy, one brain metastasis and one ependymoma.
  • CONCLUSIONS: Radiosurgery is a safe and reliable technique to treat benign and malignant intracraneal lesions.
  • [MeSH-major] Brain Diseases / surgery. Brain Neoplasms / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353882.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


80. Pollock BE: An evidence-based medicine review of stereotactic radiosurgery. Prog Neurol Surg; 2006;19:152-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Stereotactic radiosurgery has been increasingly utilized to manage a wide variety of indications including vascular malformations, benign and malignant tumors, and functional disorders.
  • Two studies provide level 1 evidence showing an improvement in local tumor control or survival for patients with 1-3 brain metastases having radiosurgery in conjunction with whole brain radiation therapy when compared to patients having whole brain radiation therapy alone.
  • [MeSH-major] Cardiovascular Abnormalities / surgery. Epilepsy / surgery. Evidence-Based Medicine. Nervous System Neoplasms / surgery. Radiosurgery / standards. Trigeminal Neuralgia / surgery

  • MedlinePlus Health Information. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033153.001).
  • [ISSN] 0079-6492
  • [Journal-full-title] Progress in neurological surgery
  • [ISO-abbreviation] Prog Neurol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 99
  •  go-up   go-down


81. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP: mTOR is activated in the majority of malignant melanomas. J Invest Dermatol; 2008 Apr;128(4):980-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, only 3/67 benign nevi (4%) were moderately positive, and none were strongly positive.
  • These data indicate that mTOR activation is very strongly associated with malignant, compared to benign, melanocytic lesions.
  • The proliferation of three melanoma-derived lines was blocked by the mTOR inhibitor rapamycin, indicating that mTOR activation is a growth-promoting factor in melanoma-derived cells. mTOR is directly activated by the small guanosine triphosphatase Ras homolog enriched in brain (Rheb), in a farnesylation-dependent manner.
  • [MeSH-major] Melanoma / enzymology. Melanoma / pathology. Protein Kinases / metabolism. Skin Neoplasms / enzymology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation / drug effects. DNA Mutational Analysis. Humans. Nevus / enzymology. Nevus / pathology. Phosphorylation. Protein Kinase Inhibitors / pharmacology. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins p21(ras) / genetics. Ribosomal Protein S6 / metabolism. Sirolimus / pharmacology. TOR Serine-Threonine Kinases

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914450.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK 51052
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Ribosomal Protein S6; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); W36ZG6FT64 / Sirolimus
  •  go-up   go-down


82. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Mar 1;67(5):1412-7 [1991305.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):976 [9255263.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):631-6 [9199633.001]
  • [Cites] Semin Diagn Pathol. 1995 May;12(2):193-206 [7638451.001]
  • [Cites] J Thorac Imaging. 2002 Jul;17 (3):227-9 [12082375.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(2):152-4 [2163798.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):207-14 [15043310.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):167-75 [2830799.001]
  • [Cites] J Laryngol Otol. 2004 Sep;118(9):724-6 [15509374.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3 [11242234.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Sep 3;129(36):1854-7 [15368156.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1823-4 [8651794.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):425-9 [10208464.001]
  • [Cites] Surg Neurol. 1988 May;29(5):410-3 [3363477.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC: Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol; 2005 Oct;89(10):1270-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PET/CT scans were used as a screening tool at the time of their initial diagnosis.
  • Brain involvement was also present in one patient.
  • In seven patients (13.4%) PET/CT imaging detected benign lesions in the bone, lung, lymph nodes, colon, and rectum.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Spinal Neoplasms / radiography. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Eye (Lond). 1998;12 ( Pt 6):945-8 [10325992.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] JAMA. 2003 Dec 24;290(24):3199-206 [14693872.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:72S-81S [14736838.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):272-8 [14960647.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2438-44 [15197206.001]
  • [Cites] Br J Ophthalmol. 2004 Aug;88(8):1095-7 [15258035.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):537-40 [15325198.001]
  • [Cites] Cancer. 1974 Oct;34(4):1001-4 [4424282.001]
  • [Cites] Arch Ophthalmol. 1982 Jun;100(6):939-40 [7092632.001]
  • [Cites] Arch Ophthalmol. 1986 Nov;104(11):1624-5 [3778275.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):326S-331S [8440916.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):107-8 [8540843.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2589-95 [9215829.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):201-8 [9261748.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1151-9 [10091801.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • (PMID = 16170114.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC1772897
  •  go-up   go-down


84. Ge P, Luo Y, Fu S, Ling F: Recurrent epidermoid cyst with malignant transformation into squamous cell carcinoma. Neurol Med Chir (Tokyo); 2009 Sep;49(9):442-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The histological diagnosis was epidermoid cyst.
  • The recurrent lesion was removed, and the histological diagnosis was squamous cell carcinoma.
  • Intracranial epidermoid cyst is a benign tumor which often appears hypodense on CT, so change to hyperdensity in the recurrent tumor may indicate malignant transformation.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Epidermal Cyst / pathology. Neoplasms, Second Primary / pathology. Temporal Lobe / pathology
  • [MeSH-minor] Brain Edema / etiology. Brain Edema / pathology. Brain Edema / radiography. Craniotomy. Decompression, Surgical. Diagnosis, Differential. Disease Progression. Humans. Male. Middle Aged. Neurosurgical Procedures. Predictive Value of Tests. Sensitivity and Specificity. Tomography, X-Ray Computed


85. Park KJ, Kang SH, Chae YS, Yu MO, Cho TH, Suh JK, Lee HK, Chung YG: Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas. J Neurosurg; 2010 Jan;112(1):73-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of interleukin-6 on the development of peritumoral brain edema in meningiomas.
  • OBJECT: Peritumoral brain edema (PTBE) is associated with perioperative neurological deficits in patients with meningiomas.
  • METHODS: Thirty-six benign meningiomas obtained in 36 patients were studied retrospectively.
  • RESULTS: Peritumoral brain edema was found in 16 patients (44%).
  • Neither age, sex, histological subtype, nor tumor location were related to PTBE.
  • On immunohistochemical analysis, IL-6 protein was found localized in the cytoplasm of the tumor cells, and was detected in 12 (75%) of 16 cases of edematous meningiomas, but in only 6 (30%) of 20 nonedematous cases.
  • CONCLUSIONS: The authors' results in this study indicate that IL-6 expression may contribute to the development of brain edema associated with meningiomas.
  • [MeSH-major] Brain Edema / etiology. Brain Edema / metabolism. Brain Neoplasms / surgery. Interleukin-6 / metabolism. Meningioma / surgery. Postoperative Complications
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brain / metabolism. Brain / pathology. Brain / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Retrospective Studies. Severity of Illness Index

  • Genetic Alliance. consumer health - Edema.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Neurosurg. 2010 Jan;112(1):208. Yoo, Mi-Ok [corrected to Yu, Mi-Ok]
  • (PMID = 19445568.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interleukin-6; 0 / RNA, Messenger
  •  go-up   go-down


86. Patterson CR, Acland K, Khooshabeh R: Cutaneous malignant melanoma arising in an acquired naevus of Ota. Australas J Dermatol; 2009 Nov;50(4):294-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Naevus of Ota is a dermal melanocytosis most commonly found in black or Asian skin and is usually a benign malformation, but with a low risk of melanoma.
  • The lesion, deceptively, had no clinically suspicious features, but investigation revealed an aggressive cutaneous malignant melanoma, extensive orbital ring melanocytosis and metastatic brain and subsequent liver disease.
  • [MeSH-major] Melanoma / pathology. Neoplasms, Second Primary / pathology. Nevus of Ota / pathology. Orbital Neoplasms / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19916976.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


87. Park JP, Cho NH, Oh YT, Choi YD: Giant multilocular prostatic cystadenoma presenting with obstructive aspermia. Yonsei Med J; 2007 Jun 30;48(3):554-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Giant multilocular prostatic cystadenoma (GMPC) is a rare benign tumor involving the prostate gland.
  • Microscopically, it masquerades phyllodes tumor or transitional zone hyperplasia.
  • [MeSH-major] Aspermia / pathology. Cystadenoma / pathology. Prostate / pathology. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Urol. 2000 Jan;163(1):246-7 [10604367.001]
  • [Cites] Int J Urol. 2002 Jul;9(7):410-2 [12165026.001]
  • [Cites] AJR Am J Roentgenol. 2002 Dec;179(6):1477-9 [12438038.001]
  • [Cites] Urology. 2003 Mar;61(3):644 [12639673.001]
  • [Cites] J Korean Med Sci. 1998 Oct;13(5):554-8 [9811190.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):131-5 [1989460.001]
  • [Cites] J Urol. 1993 Dec;150(6):1920-2 [8230538.001]
  • [Cites] Urology. 1996 Aug;48(2):303-5 [8753747.001]
  • [Cites] J Urol. 2004 Sep;172(3):894-9 [15310992.001]
  • (PMID = 17594169.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2628090
  •  go-up   go-down


88. Riemenschneider MJ, Reifenberger G: Molecular neuropathology of gliomas. Int J Mol Sci; 2009 Jan;10(1):184-212
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomas are the most common primary human brain tumors.
  • They comprise a heterogeneous group of benign and malignant neoplasms that are histologically classified according to the World Health Organization (WHO) classification of tumors of the nervous system.
  • Over the past 20 years the cytogenetic and molecular genetic alterations associated with glioma formation and progression have been intensely studied and genetic profiles as additional aids to the definition of brain tumors have been incorporated in the WHO classification.
  • In fact, first steps have been undertaken in supplementing classical histopathological diagnosis by the use of molecular tests, such as MGMT promoter hypermethylation in glioblastomas or detection of losses of chromosome arms 1p and 19q in oligodendroglial tumors.
  • [MeSH-major] Biomarkers, Tumor. Brain Neoplasms / metabolism. Glioma / metabolism
  • [MeSH-minor] Animals. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Gene Expression Profiling. Humans. Molecular Diagnostic Techniques. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2006 Sep 20;24(27):4412-7 [16983109.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5419-26 [17135643.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):129-36 [17031656.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):583-93 [16909125.001]
  • [Cites] Oncogene. 2007 Feb 15;26(7):1088-97 [16909113.001]
  • [Cites] Clin Cancer Res. 2007 Apr 1;13(7):2038-45 [17404084.001]
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):1137-43 [11238062.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):133-43 [11303789.001]
  • [Cites] Brain Pathol. 2001 Apr;11(2):159-68 [11303791.001]
  • [Cites] Acta Neuropathol. 2001 Mar;101(3):185-9 [11307615.001]
  • [Cites] Am J Pathol. 2001 Jul;159(1):359-67 [11438483.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Aug;60(8):808-16 [11487055.001]
  • [Cites] J Natl Cancer Inst. 2001 Aug 15;93(16):1246-56 [11504770.001]
  • [Cites] Acta Neuropathol. 2001 Jul;102(1):69-74 [11547953.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):917-20 [11556548.001]
  • [Cites] Neurology. 2001 Oct 9;57(7):1278-81 [11591848.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Nov;60(11):1099-104 [11706939.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Dec;60(12):1170-80 [11764089.001]
  • [Cites] Acta Neuropathol. 2002 Feb;103(2):152-6 [11810181.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Jan;61(1):58-63 [11829344.001]
  • [Cites] Int J Cancer. 2002 Mar 20;98(3):370-5 [11920588.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):929-39 [11953826.001]
  • [Cites] J Pathol. 2002 Jun;197(2):238-44 [12015749.001]
  • [Cites] Acta Neuropathol. 2002 Aug;104(2):206-8 [12111364.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):416-27 [12112531.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3054-64 [12374672.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Oct;61(10):896-902 [12387455.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2133-41 [12466129.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Dec;61(12):1092-9 [12484572.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):476-87 [12600941.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):752-7 [12640683.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jul 15;144(2):134-42 [12850376.001]
  • [Cites] Mol Carcinog. 1993;8(2):74-80 [8397797.001]
  • [Cites] Oncogene. 1994 Mar;9(3):949-54 [8108140.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4299-303 [8044775.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6321-4 [7987821.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):199-205 [8703845.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Neurogenetics. 2001 Jul;3(3):159-62 [11523567.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):853-7 [9284834.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):341-6 [9482185.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Apr;21(4):340-6 [9559346.001]
  • [Cites] Acta Neuropathol. 1998 Jun;95(6):559-64 [9650746.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Jan 1;108(1):84 [9973931.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):123-9 [10068201.001]
  • [Cites] Am J Pathol. 1999 Aug;155(2):627-32 [10433955.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1061-8 [10515229.001]
  • [Cites] Oncogene. 2008 Aug 7;27(34):4745-51 [18408760.001]
  • [Cites] Int J Cancer. 2008 Nov 1;123(9):2080-6 [18709645.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Brain Pathol. 2004 Oct;14(4):372-7 [15605984.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Dec;63(12):1236-42 [15624760.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1119-28 [15709179.001]
  • [Cites] Acta Neuropathol. 2005 Jan;109(1):93-108 [15685439.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2368-76 [17285580.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1445-53 [17456751.001]
  • [Cites] Brain Pathol. 2007 Jan;17(1):5-10 [17493032.001]
  • [Cites] Cancer Res. 1999 Dec 15;59(24):6091-6 [10626796.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] Br J Cancer. 2000 Mar;82(6):1218-22 [10735509.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Jun;59(6):539-43 [10850866.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Dec;67(12):1194-204 [19018242.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):656-70 [15316624.001]
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):193-9 [15799819.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2565-71 [15805250.001]
  • [Cites] Cancer Lett. 2005 Sep 8;227(1):75-81 [16051033.001]
  • [Cites] Ann Neurol. 2005 Aug;58(2):322-6 [16049942.001]
  • [Cites] Int J Cancer. 2005 Oct 20;117(1):95-103 [15880582.001]
  • [Cites] Mol Cancer. 2005;4:35 [16156899.001]
  • [Cites] Cancer. 2005 Oct 15;104(8):1693-9 [16116609.001]
  • [Cites] Cancer Cell. 2005 Oct;8(4):323-35 [16226707.001]
  • [Cites] PLoS One. 2007;2(6):e576 [17593975.001]
  • [Cites] Oncogene. 2007 Jul 26;26(34):5010-6 [17311001.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):363-70 [17610521.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2503-10 [18302158.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] J Clin Oncol. 2008 Jun 20;26(18):3015-24 [18565887.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Sep;62(9):927-35 [14533782.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Oct;62(10):1052-9 [14575240.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7600-5 [14633674.001]
  • [Cites] Neuropathol Appl Neurobiol. 2003 Dec;29(6):574-83 [14636164.001]
  • [Cites] Acta Neuropathol. 2004 Mar;107(3):277-82 [14730454.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):296-307 [15057289.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jun;151(2):182-3 [15172758.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5048-50 [15289301.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] J Neuropathol Exp Neurol. 1974 Jul;33(3):456-71 [4365915.001]
  • [Cites] Clin Neuropathol. 1982;1(4):139-50 [6188569.001]
  • [Cites] J Neuropathol Exp Neurol. 1988 Mar;47(2):101-18 [3339369.001]
  • [Cites] Cancer Res. 1991 Nov 15;51(22):6202-5 [1933879.001]
  • [Cites] Cell. 1992 Apr 17;69(2):275-81 [1568247.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] Cancer Res. 1992 Aug 15;52(16):4550-3 [1322795.001]
  • [Cites] Am J Pathol. 2005 Nov;167(5):1379-87 [16251422.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1759-65 [16541434.001]
  • [Cites] Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2070-9 [16609018.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):3987-91 [16618716.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] Cancer Biol Ther. 2006 Mar;5(3):300-4 [16410724.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5618-23 [16740698.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • (PMID = 19333441.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2662467
  • [Keywords] NOTNLM ; 19q / 1p / Glioblastoma / MGMT / biomarker / ependymoma / genetics / molecular diagnostics / oligodendroglioma / profiling
  • [General-notes] NLM/ Original DateCompleted: 20100621
  •  go-up   go-down


89. Payne GS, Leach MO: Applications of magnetic resonance spectroscopy in radiotherapy treatment planning. Br J Radiol; 2006 Sep;79 Spec No 1:S16-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While MRI and CT provide images of excellent spatial resolution, they do not always provide sufficient contrast to identify tumour extent or to identify regions of high cellular activity that might be targeted with boost doses.
  • The method is currently under evaluation, in particular in brain (where MRS has been shown to differentiate between many tumour types and grades) and in prostate (where cancer may be distinguished from normal tissue and benign prostatic hypertrophy).
  • The contrast achieved with MRS, based on tissue biochemistry, therefore provides a promising alternative for identifying tumour extent and regions of high metabolic activity.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Magnetic Resonance Spectroscopy. Patient Care Planning. Prostatic Neoplasms / radiotherapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Male

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16980681.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


90. Ligon AH, Moore SD, Parisi MA, Mealiffe ME, Harris DJ, Ferguson HL, Quade BJ, Morton CC: Constitutional rearrangement of the architectural factor HMGA2: a novel human phenotype including overgrowth and lipomas. Am J Hum Genet; 2005 Feb;76(2):340-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although somatic mutations in a number of genes have been associated with development of human tumors, such as lipomas, relatively few examples exist of germline mutations in these genes.
  • Here we describe an 8-year-old boy who has a de novo pericentric inversion of chromosome 12, with breakpoints at p11.22 and q14.3, and a phenotype including extreme somatic overgrowth, advanced endochondral bone and dental ages, a cerebellar tumor, and multiple lipomas.
  • His chromosomal inversion was found to truncate HMGA2, a gene that encodes an architectural factor involved in the etiology of many benign mesenchymal tumors and that maps to the 12q14.3 breakpoint.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 1;59(19):4793-7 [10519386.001]
  • [Cites] Nat Genet. 2000 Apr;24(4):377-80 [10742101.001]
  • [Cites] J Biol Chem. 2000 May 12;275(19):14394-400 [10747931.001]
  • [Cites] Cancer Genet Cytogenet. 2000 May;119(1):70-3 [10812175.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):160-5 [11120880.001]
  • [Cites] Mod Pathol. 2001 Apr;14(4):311-7 [11301347.001]
  • [Cites] Biochim Biophys Acta. 2001 May 28;1519(1-2):13-29 [11406267.001]
  • [Cites] DNA Cell Biol. 2001 Jun;20(6):349-57 [11445006.001]
  • [Cites] Carcinogenesis. 2001 Oct;22(10):1583-91 [11576996.001]
  • [Cites] Cancer Res. 2003 Mar 15;63(6):1351-8 [12649198.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jun;143(2):160-8 [12781451.001]
  • [Cites] Int J Oncol. 2003 Aug;23(2):363-7 [12851685.001]
  • [Cites] Hum Mutat. 2003 Sep;22(3):183-98 [12938083.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Jan;39(1):82-7 [14603445.001]
  • [Cites] Science. 2003 Nov 7;302(5647):1033-5 [14526086.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1132-40 [14614053.001]
  • [Cites] Genome Res. 2004 May;14(5):852-9 [15078857.001]
  • [Cites] Cancer Genet Cytogenet. 1990 Feb;44(2):153-67 [2153439.001]
  • [Cites] Nature. 1990 Apr 26;344(6269):876-9 [1970421.001]
  • [Cites] Cancer Res. 1991 Jan 1;51(1):422-33 [1988102.001]
  • [Cites] Cancer Genet Cytogenet. 1993 Jan;65(1):27-31 [8381711.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5604-12 [8355703.001]
  • [Cites] Genes Dev. 1994 Feb 1;8(3):277-89 [8314082.001]
  • [Cites] Genomics. 1995 Mar 20;26(2):265-71 [7601452.001]
  • [Cites] Cell. 1995 Jul 14;82(1):57-65 [7606786.001]
  • [Cites] Nature. 1995 Aug 31;376(6543):771-4 [7651535.001]
  • [Cites] Nat Genet. 1995 Aug;10(4):436-44 [7670494.001]
  • [Cites] Oncogene. 1996 Feb 1;12(3):515-21 [8637707.001]
  • [Cites] Hum Mol Genet. 1996 Sep;5(9):1229-35 [8872461.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2276-80 [9187132.001]
  • [Cites] Leuk Lymphoma. 1997 Aug;26(5-6):603-7 [9389367.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Jun;103(2):175-7 [9614921.001]
  • [Cites] Oncogene. 1998 Jul 30;17(4):413-8 [9696033.001]
  • [Cites] Am J Hum Genet. 1999 Jul;65(1):111-24 [10364523.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Aug;25(4):316-22 [10398424.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Mar;24(3):278-82 [10451709.001]
  • (PMID = 15593017.001).
  • [ISSN] 0002-9297
  • [Journal-full-title] American journal of human genetics
  • [ISO-abbreviation] Am. J. Hum. Genet.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P01 GM061354; United States / NIGMS NIH HHS / GM / GM61354
  • [Publication-type] Case Reports; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein
  • [Other-IDs] NLM/ PMC1196379
  •  go-up   go-down


91. Matschke J, Tsokos M: Sudden unexpected death due to undiagnosed glioblastoma: report of three cases and review of the literature. Int J Legal Med; 2005 Sep;119(5):280-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although glioblastomas are among the most common primary cerebral neoplasms, sudden death due to these tumors is an uncommon event.
  • A comprehensive literature review on cases of sudden death due to primary cerebral neoplasms published so far revealed a total of 83 cases with only ten cases of glioblastoma (12%), whereas 55 of these cases were due to histological benign tumors (66%).
  • [MeSH-major] Brain Neoplasms / diagnosis. Death, Sudden / etiology. Glioblastoma / diagnosis<